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GENETIC EVOLUTION AND PROGNOSTIC DETERMINANTS OF PANCREATIC CANCER
ON LONGITUDINAL LIQUID BIOPSIES

Vincent Bernard Pagan, MS
Advisory Professor: Anirban Maitra, MBBS

Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest 5-year survival rates amongst
solid tumors. As early detection of PDAC is unusual and typically incidental, most patients
present with locally advanced and metastatic disease where effective therapeutic strategies
remain a significant unmet need. Specifically, surrogate biomarkers for tumor monitoring of
PDAC may lead to improved elucidation of clinical actionability and prognostic potential. On the
other hand, tumor tissue is rarely sampled in patients presenting with de novo or recurrent
metastatic PDAC, apart from a fine needle aspiration or a core needle biopsy performed for
diagnosis. This precludes the opportunity for elucidating molecular underpinnings of cancer
recurrence, chemoresistance, and therapeutic decision-making in advanced disease patients
over the course of their therapy. For this reason, we aim to use so called “liquid biopsies” in the
form of circulating nucleic acids and exosomes as a strategy that is amenable to longitudinal,
relatively non-invasive sampling. Circulating tumor DNA and circulating exosomes contain
genetic cargo representative of the neoplastic cells from which they are released and can serve
as a reliable surrogate of the patient’s tumor DNA, enabling a new way of interrogating cancers.
We demonstrate that serial quantitative measurements of these tumor nucleic acid sources in
circulation can provide clinically relevant predictive and prognostic information in pancreatic
cancer patients, including anticipation of impending disease progression and putative
mechanisms of resistance to ongoing therapy. We also describe our ability to specifically capture
tumor material in circulation following a comprehensive characterization of the pancreatic cancer
exosomal “surfaceome”. By leveraging an immune-capture approach paired with ultrasensitive
molecular barcoding techniques, we are able to increase our sensitivity of detection of rare
v

molecules in circulation that are derived from the tumor. Ultimately, this has implications for
stratification of patients into therapeutic “buckets” through a personalized approach that may lead
to greater survival benefits in PDAC.
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Chapter 1 – Introduction

With permission this chapter is based upon “Bernard V, Fleming J, Maitra A. Molecular and
Genetic Basis of Pancreatic Carcinogenesis: Which Concepts May be Clinically Relevant?
Surg Oncol Clin N Am 2016;25:227-38.”
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Chapter 1 – Introduction
Pancreatic Cancer
Although rare (2% of cancer cases), pancreatic ductal adenocarcinoma (PDAC) is the
fourth leading cause of cancer-related deaths in this country. In contrast to the decline of cancer
related deaths from other malignancies, the alarming rise in incidence of PDAC is projected to
make it the second leading cause of cancer related death by 2030 (1). The relatively equal
incidence and mortality rates in PDAC have led to its dire prognosis, with a 5-year survival rate
of only 4% (2). The lethality of PDAC is attributed in part to the lack of early detection, with the
majority of patients (~85%) presenting with locally advanced or metastatic disease. Diagnosis at
these late stages is due to the absence of specific symptoms and clinical findings due to its
retroperitoneal location, and a lack of serological tests that are sufficiently sensitive and specific.
In addition, the therapeutic landscape of PDAC is limited, with Gemcitabine and FOLFIRINOX
(folinic acid, fluorouracil, irinotecan, and oxaliplatin) being the two main regimens with low overall
response rates. The main oncogenic driver mutation, observed in >90% of PDAC, KRAS (vKiras2 Kirsten rat sarcoma viral oncogene homolog) has also compounded its poor survival rate
due to its “undruggability”; although chemotherapeutic strategies may exist in certain targetable
cases as discussed below.
Advances in next generation sequencing (NGS) technologies have allowed for a detailed
insight into the genomic landscape of PDAC, in order to better understand how molecular
alterations contribute to disease initiation and progression. In particular, dissecting the molecular
events involved in the progression of PDAC from pancreatic intraepithelial neoplasia (PanINs)
lesions to invasive carcinoma, are being achieved with possible implications to targeted
therapeutic approaches.
Multi-step progression of PDAC
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The progression of PDAC from a normal cell to an invasive adenocarcinoma involves the
accumulation of inherited and/or acquired mutations throughout the span of up to approximately
20 years (3). This highlights the importance of exploiting this window of progression to develop
new screening methods to provide curative surgical approaches. This progression involves the
evolution of histologically recognized precursor lesions known as pancreatic intraepithelial
neoplasias (PanINs). As of date of this publication, the categorization of PanIN is divided into low
grade (PanIN-1A and 1B), intermediate (PanIN-2), and high-grade PanIN-3)(4), although there
is an emerging consensus in the clinical research community to move to a simplified two-tier
classification of “low” grade (PanIn-1 and -2) and “high” grade PanINs (PanIN-3). This is based
on observations that, while PanIN-1 and-2 lesions can be found even in the absence of cancer,
PanIN-3 is almost never found without concomitant invasive neoplasia. Genetic alterations can
be grouped into those that arise in precursor lesions and are usually, albeit not always, found in
the concomitant PDAC, versus those that arise during subclonal evolution of the infiltrating
carcinoma resulting in genetic heterogeneity.
One of the earliest genetic events involved in PDAC pathogenesis is an activating point
mutation in the KRAS oncogene, an oncogenic driver mutation found in more than 90% of all
PDACs. Subsequent genetic aberrations include inactivation of tumor suppressor genes
including CDKN2A, TP53, and SMAD4, which encode for p16INK4A, p53, and Smad4,
respectively, and contribute to the histological evolution of these precursor lesions. Together,
these four alterations comprise the “big four” in PDAC, although many other recurrent somatic
mutations are found in lower frequencies (5-10%) of cases, including those that afflict particular
functional pathways in the cancer cell, such as DNA damage repair or chromatin regulation.
Among the population of noninvasive precursor lesions, it is also important to recognize
intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs).
Although histologically distinct from the microscopic PanIN lesions, these cystic precursor lesions
share similar diver mutations including point mutations in the KRAS oncogene(5), and
inactivating mutations in p53 and p16, with SMAD4 loss typically not being found in IPMNs (6,
3

7). Among the unique drivers found in both IPMNs and MCNs, are inactivating mutations in
RNF43, encoding for an ubiquitin ligase that has a role in WNT signaling inhibition(5). IPMNs
also contain point mutations in the GNAS gene, which result in constitutively active guanine
nucleotide-binding protein due to loss of intrinsic GTPase activity preventing hydrolysis of GTP
(8).

KRAS

Under physiological conditions, activation of Ras protein is induced through growth factor
receptor signaling, which promotes Ras activity through transitory binding to GTP. This results in
the interaction of Ras with a variety of downstream effectors that govern proliferation, cell
division, survival, and gene expression such as the RAF-mitogen-activated protein kinase and
phosphoinositide 3-kinase pathways (9). Through an intrinsic GTPase mechanism and GTPaseactivating proteins, Ras can then hydrolyze GTP to GDP to inactivate itself. It is this intrinsic
GTPase activity that is altered in the activating point mutation of KRAS, which results in an
inability to hydrolyze GTP allowing for a constitutively active protein that no longer relies on
external stimuli. The most common “hotspot” mutation in the KRAS oncogene occurs at codon
12, followed by codon 13, and less frequently codon 61; emerging genomic data suggests that
the specific codon involved might have an impact on disease prognosis, underscoring differences
in Ras function (10, 11).

Telomere shortening
Telomeres are repetitive nucleoprotein complexes found at the end chromosomes that
have a role in genomic stability by protecting against chromosomal degradation and chromosome
end fusion.

In PDAC, shortened telomeres lengths that potentially lead to chromosomal

abnormalities can be detected in early lesions such as IPMNs and nearly universally in all PanINs
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(12). Genomic instability of this kind will typically lead to cell death unless cells are able to
inactivate tumor suppressor mechanisms as described below.

CDKN2A
The most commonly mutated tumor suppressor in PDAC (~95%) is an inactivation of
cyclin-dependent kinase inhibitor 2A gene (CDKN2A), encoding for the cell cycle checkpoint
protein, p16INK4A(13). Inactivation of CDKN2A in PDAC can occur via several different
mechanisms, including mutation, genomic deletions, and promoter hypermethylation resulting in
epigenetic silencing. (14). The encoded protein p16INK4A functions as a cyclin-dependent kinase
inhibitor, specifically of CDK4 and CDK6 thereby preventing the phosphorylation of the
retinoblastoma protein and blocking G1-S transition(15). Loss of this protein thus results in
unregulated cell cycle transition.

TP53
Aberrations of TP53, which encodes for p53, are typically a later event in the multiprogression of PDAC, often arising in PanIN-3 lesions, and is mutated in up to 70% of tumors(16).
As the master guardian of the genome, p53 is involved in cell cycle arrest, DNA repair, blocking
of angiogenesis, and induction of apoptosis in response to DNA damage or environmental
stressors. Loss of this protein allows for DNA damage and external stressors to go unchecked,
thereby promoting genomic instability and aberrant proliferation.

SMAD4
SMAD4 (DPC4, SMAD family member 4 gene), which encodes for the Smad4 protein, is
inactivated in approximately 50% of PDACs as a late event in its progression (PanIN-3 –
Carcinoma) (17). As a downstream effector of transforming growth factor-β (TGF- β), loss of
SMAD4 activity leads to tumor promotion by relieving the growth inhibitory effect of TGF- β
signaling (18).
5

Clinical Relevance of Core PDAC Mutations
Although pancreatic cancers have been shown to harbor an average of 63 genetic
mutations, the genomic landscape of PDAC is faithfully represented by these four genomic
mutations (KRAS, CDKN2A, TP53, and SMAD4)(10). The high degree of mutational
concordance at these four loci between primary and metastatic sites of individual cancers (19)
suggests these are so-called founder mutations. This describes a mutation present in all samples
from a single patient, thus sharing a common ancestor, which likely originated during PanIN
progression (3, 12).

Of note, PDACs continue to accumulate genetic alterations through

subclonal evolution throughout their natural history, the vast majority of which are so-called
“passenger” mutations that have little functional impact on progression, while a minor fraction are
so-called “progressor” mutations, and do have a deleterious consequence on disease
progression. In any case, a variable combination of the “big four” is altered in most PDAC cases,
with nearly all cancers showing at least KRAS mutations in conjunction with one or more of the
three tumor suppressors. Yachida et. al. describe correlations of the status of these 4 genes to
disease progression, metastatic failure, and overall survival, with patients with 3-4 of these
mutated driver genes demonstrating worse overall survival (19). When looking at the genes
individually, there is no significant difference in outcome in patients with KRAS and CDKN2A
mutations, but TP53 and SMAD4 mutations were evidently associated with widespread
metastatic disease and worse clinical outcomes (20, 21). In particular, SMAD4 status in PDAC
(measured using immunohistochemical expression for the Smad4 protein) is being used to
provide guidance towards tailoring treatment with systemic chemotherapy, as patients with
Smad4-null tumors are most likely to develop widely metastatic disease. (22).

Germline Variants
With estimates of 10% of PDAC patients having a family history of the disease, elucidation
of the PDAC genome has also contributed towards risk assessment and early detection in the
6

context of familial pancreatic cancers(23, 24). Among hereditary pancreatic cancer susceptibility
genes, STK11/LKB1, associated with Peutz-Jegher syndrome, is correlated with one of the
highest risks of familial pancreatic cancers with approximately 132x relative lifetime risk (25).
PRSS1 and SPINK1 germline mutations are seen hereditary pancreatitis families with a 50-80x
relative lifetime risk, or 30-44% risk, of developing PDAC (26-28). P16/CDKN2A germline
mutations, associated with familial atypical multiple mole melanoma syndrome (FAMMM), entails
a 38x (17% lifetime risk) increased risk of developing PDAC (29). Additional germline variants
associated with increased PDAC risk are clustered into defects of DNA repair pathways. This
includes members of the Fanconi anemia pathway such as FANC-C, FANC-G, and PALB2,
whose encoded proteins interact with that of BRCA2, and are associated to young onset
pancreatic cancer (30). BRCA1/BRCA2 mutations, which are associated with familial breast and
ovarian cancers, have a 3.5-10x estimated relative risk (31-33). Lynch syndrome, caused by
mutations in DNA mismatch repair (MMR) genes, MLH1, MSH2, MSH6 or PMS2, have an
estimated 3.68% lifetime risk (34). Patients with ATM (Ataxia telangiectasia mutated) germline
mutations have also demonstrated a predisposition for PDAC (35). Further elucidation of
additional genes associated with familial PDAC may have implications for risk assessment and
surveillance in affected family members. Detection of these germline mutations in patients is
also important in the context of therapy as a way to exploit synthetic lethal interactions in the
case of DNA repair pathways as described below.

Core Signaling pathways in pancreatic cancer
Large scale sequencing efforts have uncovered novel mutated genes in PDAC, as well as
revealing multiple core signaling pathways that are affected throughout its carcinogenesis. In
2008, Jones et. al. performed polymerase chain reaction (PCR)-based exome sequencing of
primary and metastatic tumors (10). Their data supported the role of the 4 main genetic drivers
in pancreatic cancer, KRAS, CDKN2A, TP53, SMAD4, and identified genetic alterations in many
other critical pathways recognized as “hallmarks of cancer”, at least some of which appear to
7

have a prognostic influence in subsequent studies (11, 36). The core “hallmarks of pancreatic
cancer” pathways that appear to be targeted in PDAC are highlighted in Table 1 with some salient
examples of genes mutated in each pathway.
Table 1: Core hallmarks of pancreatic cancer pathways

Apoptosis

CASP10, VCP, CAD

DNA damage control

TP53, RANBP2, EP300

Regulation of G1/S phase

CDKN2A, FBXW7, APC2

transition
Hedgehog signaling

GLI1, GLI3, BMPR2

Homophilic cell adhesion

CDH1, CDH2, CDH10, PCDH15

Integrin signaling

ITGA4, ITHA9, LAMA1, FN1

C-Jun N-terminal kinase

MAP4K3, TNF, ATF2

signaling
KRAS signaling

KRAS, MAP2K4, RASGRP3

Regulation of invasion

ADAM11, ADAM12, DPP6, MEP1A

Small GTPase-dependent

PLXNB1, AGHGEF7, PLCB3, RP1

TGF-B signaling

SMAD4, SMAD3, TGFBR2, BMPR2

Wnt/Notch signaling

MYC, GATA6, WNT9A, MAP2, TCF4

The altered genes in these respective pathways varied among separate patient tumors, such
as the TGF-B pathway being altered by a SMAD4 mutation in one patient versus a BMPR2
8

mutation in another, but the pathway in itself is often altered among samples. With this new
global view of the PDAC genome as a set of a specific and limited number of pathways involved,
we can begin to simplify the genetic heterogeneity that is intrinsic to these tumors and develop
strategies to target the physiological effects of the mutations rater than the specific mutations
themselves. By targeting key nodes involved in these pathways, such as the impaired ability to
repair DNA, or altered cell cycle control, we may be able to circumvent the inevitable resistance
that these tumors develop following targeted gene therapies.
In 2012 Biankin et. al. performed next generation sequencing of whole exomes and copy
number analysis of primary resected PDAC from 142 patients, under the umbrella of the
International Cancer Genome Consortium (ICGC) (37). This study reaffirmed the core signaling
pathways identified by Jones et. al. (10), and also discovered novel mutated genes in these core
signaling pathways including those involved in DNA damage repair (ATM), which is also shown
to have a role in familial PDAC. Novel gene signatures were also identified in axon guidance
pathway genes (SLIT/ROBO signaling) which are known to have a role in neuronal migration and
positioning during embryogenesis with potential implications in cancer cell survival, growth,
invasion and angiogenesis (38). Deregulation of these axon guidance genes was shown to have
a role in tumor initiation and progression in the context of PDAC. Particularly, low ROBO2 or
high ROBO3 expression was seen to be associated to poor patient survival. High expression of
Semaphorin signaling molecules, specifically SEMA3A and PLXNA1 were also determined to be
associated with poor patient survival. The ICGC team’s methodology provided them the
opportunity to identify potential novel drivers of pancreatic cancer, and new nodal signaling
targets involving axon guidance, where therapeutics are currently developed for neuronal
regeneration after injury (39). Again, we see the importance of developing therapeutics based on
molecular phenotypes as further elucidation of genetic heterogeneity provides a cumbersome
picture of pancreatic cancer.
In 2015, the next iteration of the ICGC PDAC dataset was published by Waddell et. al, who
performed whole genome sequencing and copy number variation analysis of 100 PDACs, and
9

demonstrated chromosomal rearrangements that led to genetic aberrations(40). These structural
rearrangements led to gene deletions, amplifications and fusions that are associated with driving
carcinogenesis while presenting opportunities for clinical actionability and biomarkers of
therapeutic response for platinum based chemotherapies. This led to the classification of PDACs
into 4 subtypes based on structural rearrangement profiles (Table 2).

Table 2: PDAC structural rearrangements profiles

Stable

Small number of structural rearrangements (<50) with
defects in cell cycle characterized by aneuploidy.

Locally

Presence

of

intra-chromosomal

rearrangements

rearranged

classified as complex: leading to chromothripsis or
breakage-fusion-bridge cycles; or focal copy number
gains in genes such as KRAS, SOX9, GATA6 and
potential therapeutic targets like ERBB2, MET, CDK6,
PIK3CA, and PIK3R3.

Scattered

Chromosomal

aberrations

due

to

structural

rearrangements (50-200) throughout the genome.
Unstable

Widespread structural rearrangements (>200) with
genomic instability pointing towards somatic or germline
deleterious mutations in DNA maintenance pathways
(e.g. BRCA1, BRCA2, and PALB2) which suggest
sensitivity to DNA damaging agents. A subset of these
patients who were treated with platinum based therapy at
tumor recurrence demonstrated robust or exceptional
responses.
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In addition to the classic “big four” and alterations in genes whose products are involved in
DNA maintenance, the Waddell et al study highlighted the emerging importance of chromatin
regulatory genes in the pathogenesis of PDAC. In particular, mutations of genes whose encoded
proteins are involved in histone modification (MLL2, MLL3, KDM6A) and SWI/SNF genes that
regulate how DNA is packaged in nucleosomes. (ARID1A, ARID2) emerged as a family of driver
genes with unequivocal significance in PDAC. A recent whole exome study of resected PDAC
patients by Sausen et. al. found strikingly favorable impact of harboring MLL2 or MLL3 mutations
in the corresponding tumor, although the functional basis for this observation is still being
elucidated (36). Inactivation of other tumor suppressors such as ROBO1, ROBO2, SLIT2, and
RNF43 also demonstrate the role of aberrant WNT signaling in PDAC, as well as the potential
for sensitivity that these mutations may confer to WNT inhibitors (41).
Overall, the recent series of exome studies in PDAC have suggested that a major mechanism
of genomic instability and damage in pancreatic cancer involves structural variations and their
potential clinical relevance. This supports the role of platinum based regimens such as
FOLFIRINOX in a subgroup of patients that are both able to tolerate the regimen and contain a
signature of impaired DNA maintenance pathways due to an unstable structural rearrangement
phenotype within their tumors. It may also provide a model for patient stratification for PARP-1
inhibitor therapy as current clinical trials are predominantly restricted to patient populations with
BRCA1 and BRCA2 germline defects. This new model also allows for a surrogate measure of
defects in DNA maintenance where there may be a larger population that may benefit from such
therapies who have non-BRCA pathway gene mutations, but whose unstable tumor subtype
suggests sensitivity to DNA damaging agents.
More recently, Bailey et. al. have used exome and RNA profiling on 450 PDAC samples in
the ICGC cohort to define 4 subtypes of PDAC based on differential gene expression signatures
with distinct biological underpinnings: Squamous, Pancreatic Progenitor, ADEX (aberrantly
differentiated endocrine exocrine) and Immunogenic (unpublished data, Biankin et al personal
communication). While each of these molecular subtypes is enriched in a particular histological
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variant (for example, the nom de plume for Squamous subtype arising from its enrichment of
adenosquamous carcinomas in this subset), the intent of this expression signature is to tease
out biological distinctions that might underlie PDACs that look identical at the morphological level.
Not surprisingly, as is being increasingly noted across pan-cancer profiling datasets, there exists
striking molecular similarities between subtypes across cancer types than within subtypes in a
single cancer. Thus, the squamous subtype of PDAC has greater similarities to the so-called
basal type cancers observed in head and neck and triple negative breast cancers (characterized
by a overriding p63-driven signature) than to the other three PDAC subtypes.
Among clinical actionability in these subtypes, MYC amplifications have been found to be
associated to the adenosquamous subtype with a correlation to poor survival (11). Also,
appreciable differences in roles of the immune system can be identified, which may lead to
exploiting immunotherapeutic strategies. In the case of the squamous subtype, a loss of cytotoxic
T cells was associated with an increase in Toll-like receptors, CD4+ T cells and macrophages,
as well as high expression of CTLA4 and PD1 immunosuppressive pathways. Stratification
based on these subtypes may thus assist in clinical trial patient selection for therapeutics such
as PD1 and CTLA4 checkpoint inhibitors to decipher their potential role in this disease.
Many of these recent global sequencing efforts provide a biomarker-based approach in order
to identify surrogates for prognostic and therapeutic stratification. As most of the sequencing data
provided was performed on patients with surgically resectable primary tumors versus those
undergoing recurrence or falling into the locally advanced or metastatic category, the complete
picture of PDAC remains limited to a small subset of patients (~15%). Still, these efforts provide
proof of concept on how measures of aberrant molecular mechanisms may inform clinical
actionaibility using next generation sequencing techniques.
New promising strategies involving liquid biopsies are being developed as noninvasive
methods of disease detection and monitoring (42, 43). Specifically, through the use of circulating
tumor DNA (ctDNA) that is released in the blood by primary and metastatic tumors, one can
theoretically obtain a full representation of the tumor heterogeneity that is present within each
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patient. Sausen et. al. demonstrated that somatic mutation calling can be made from ctDNA in
PDAC patients to determine presence of subclinical, residual or recurrent disease following
surgical resection. Detection of this ctDNA was correlated to disease progression that even
predated standard computed tomography imaging by an average of 6 months, suggesting that
there may be an ability to treat subclinical disease before it is overtly clinically evident based on
imaging (36). Using ultrasensitive digital PCR techniques, ctDNA was detected in 43% of
surgically resectable (i.e. lower stage) PDAC patients at the time of diagnosis. Although this
study did not examine pre-diagnostic samples in patients prior to a clinical manifestation of
disease, nonetheless, it provides a potential screening approach through which high-risk
patients, such as those with family history or germline mutations, can undergo non-invasive
surveillance for the emergence of PDAC in time for curative surgical options.
Liquid biopsy has also shown promise in being able to genomically characterize tumors,
and predict chemotherapy response and resistance using next generation techniques through
both ctDNA and circulating tumor cells (CTCs) (44-46). One can thus begin to imagine how tumor
evolution and the emergence of new dominant clones can be identified using these methods to
guide therapeutic decisions in real time.
Using genomic sequencing to guide therapy
The genetic heterogeneity of PDAC as presented above is unequivocally one of the many
significant contributors to the intrinsic and acquired resistance that is characteristic of these
cancers (47). Targeting of subclonal populations will only lead to transient effects on tumor
burden, thus new strategies are required for therapeutic targeting of core pathways that are
induced by founder events. By targeting convergent phenotypes that can be elucidated through
genome sequencing of patient tumors, genomic information has the potential to guide individual
patient therapies and outcomes (48, 49).
In patients with familial PDAC, information of deleterious germline variants may provide
some success in the cases of gene mutations in double strand break repair pathways by using
therapeutics aimed at compromising additional DNA repair mechanisms such as platinum based
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therapies, mitomycin C, and PARP-1 (poly (ADP-ribose) polymerase 1) inhibitors(50-52). By
exploiting synthetic lethal approaches, which result in cancer-specific cell death through
exploitation of cancer-specific molecular aberrations, one can target base excision repair through
PARP-1 inhibition, leading the accumulation of chaotic DNA damage (53-55).
The ideal gene target in PDAC is Ras itself as it is the main oncogenic driver in more than
90% of these tumors, but efforts have so far proven ineffective (56, 57). Synthetic lethality
screens for KRAS have not been successful, but there has been some data suggesting possible
targeting of its downstream effectors such as the MEK-ERK MAPK and AKT (protein kinase B)
signaling pathway (58); unfortunately, recent clinical trials have shown unacceptable levels of
toxicities in humans when two downstream Ras effectors are inhibited (59). In the small subset
of PDAC identified as harboring wild type KRAS, sequencing studies have found mutations in
genes encoding RAS effector proteins including PIK3CA and BRAF (11). In this small subset of
cases, targeted therapies using BRAF and PI3 kinase inhibitors may beneficial.
Further work still remains to be done to determine all key components that drive PDAC.
Exploiting nodal signaling pathways vs. attacking genetic heterogeneity head on, may be the
best strategy in overcoming the advantages pancreatic cancers have over current treatment
regimens. For now, stratification of subsets of patients based on defined molecular markers into
clinical trials may prove beneficial in demonstrating the effectiveness of targeted therapies in
these populations.

Clinically relevant concepts in pancreatic cancer
While early diagnosis of PDAC remains is an unequivocal unmet need, the clinical reality is that
85% of patients present with locally advanced or distant metastatic (Stage 3 or 4) disease,
rendering their cancers inoperable. The standard of care for clinical follow up in PDAC patients,
for both de novo advanced and recurrent tumors, is to use imaging and one biochemical marker
(CA19-9). The reasons for this are manifold, including the difficulties of repeatedly sampling a
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visceral site, the costs involved for an inpatient biopsy (easily in the range of $10,000 in most
academic centers), and the lack of insurance reimbursement for tissue acquisition beyond the
initial diagnostic workup. As a result, patients with de novo advanced or recurrent disease are
treated empirically, with minimal insights into genomic underpinnings of treatment failure, in
contrast to diseases like lung cancer or melanoma, where tissue accessibility has allowed
elegant mapping of secondary mutations. In passing, it is also worth noting that the paucity of
tissues from advanced PDAC patients is an important reason why the pioneering exome
sequencing studies in PDAC, as well as the ongoing TCGA effort, are almost entirely focused on
surgically resected tumors.
Given the visceral location of the pancreas, the only biomarker strategy amenable to widespread
application in the community and to repeated sampling for monitoring treatment progress, is one
that is blood-based, since direct tissue biopsy involves skillful and expensive medical
procedures not applicable for general population screening or monitoring. In terms of currently
available blood-based biomarkers for PDAC, measurement of the glycoprotein CA19-9 is the
only FDA approved assay for diagnosis and monitoring. However, in symptomatic patients,
CA19-9 only has a sensitivity and specificity that ranges in the 70-90%. Thus, it is clearly
suboptimal for diagnosis in asymptomatic patients, which is the eventual target population of
interest for early detection. While a multitude of blood-based protein biomarkers have been
tested in research settings for PDAC, none have yet made it to the clinic besides CA19-9. In
many instances, this is because they are unable to significantly improve the performance of
CA19-9, while in other scenarios, confounding variables such as chronic pancreatitis or other
non-neoplastic entities lead to false positives and obfuscate the results. Recently, there has been
an increasing reliance on using mutant DNA in serum as a cancer biomarker. The reliance on
mutant DNA over aberrantly expressed proteins stems from the recognition that somatic
mutations are pathognomonic of neoplasia, and circulating mutant DNA has not been reported
in patients with benign tumors or non-neoplastic conditions. Cancers release large quantities of
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cell free DNA (cfDNA) from their mutant genomes into the circulation, and even though much of
this cleaved into fragments 150bp or less by nucleases, sensitive PCR assays can be designed
for detecting “hot spot” mutations in genes such as KRAS, PIK3CA, BRAF, etc.. This is quite
pertinent for PDAC, where >95% of patients have KRAS mutations in their tumors. Nonetheless,
a recent study that combined isolation of cfDNA in PDAC patients with a bead-based digital PCR
technology identified KRAS mutations in 75% of patients with advanced disease, but only in 48%
with localized tumors Thus, clearly, while cfDNA has great promise, there is substantial room for
improvement in assay parameters for patients most likely to benefit from early detection. Another
limitation of cfDNA, from the context of genomic characterization of advanced tumors, is the
extensively fragmented nature of the nucleic acids, which precludes its use in most next
generation sequencing (NGS) platforms. Thus, an ideal “liquid biopsy” biomarker strategy
for early detection and treatment monitoring in PDAC would: (a) be feasible for application
using blood samples (1-2 vials) in a Point-of-Care Test (POCT) setting; (b) be paired with ultrasensitive and quantitative detection of mutant DNA for purposes of early detection and
treatment/recurrence monitoring; and (c) provide high quality nucleic acids amenable to NGS.
We this in mind, we hypothesize that liquid biopsies in the form of cfDNA and exosomal derived
DNA are a reliable surrogate of the tumor genome in PDAC patients, and can be a biospecimen
of choice for early detection, serial disease monitoring, and therapeutic stratification, without the
need for tissue acquisition. We aim to identify mutant DNA in liquid biopsies from patients with
surgically resectable and metastatic PDAC in order to query the actionable exome of PDAC for
therapy guidance.
Exosomes and other extracellular vesicles
Exosomes are extracellular vesicles (EVs) exhibiting a diameter of 40-120 nm, conceived
endogenously through the multivesicular endosome pathway and released to the extracellular
space via fusion with the plasma membrane (60, 61). Microvesicles (MVs) are a class of larger
EVs with a diameter ranging from 0.2 to 1 m and originate from the budding and fission at
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special “lipid raft” domains of the plasma membrane (62). A methodology to reliably enrich for
exosomes, but not microvesicles, currently does not exist, as there are significant overlap
between size, shape, density and cell marker profiles (63). Both are molecular vehicles reported
to transfer a variety of biochemical cargo, including protein products, RNA transcripts,
microRNAs, and fragmented DNA, but beyond their distinct biogenesis pathways and relative
diameters, the two are difficult to delineate, and as a result, are frequently used interchangeably
in literature (64-67). For the purpose of this chapter, we will use the term exosome to refer
specifically to the population of small EVs produced through the multivesicular endosome
biogenesis pathway.

Double-Stranded Genomic DNA in Circulating Exosomes
Circulating exosomes are known to facilitate intercellular communication through the
exchange of numerous biochemical products such as proteins, lipids, mRNA transcripts, miRNA,
and DNA of both chromosomal and mitochondrial origin (68). The recent identification of doublestranded high molecular weight genomic DNA within circulating exosomes has proven to be an
exciting discovery in the context of cancer liquid biopsies with translational implications for early
detection, diagnosis, monitoring, and prognostic and therapeutic stratification of solid tumors,
including deep seated visceral cancers. Specifically, exosome-derived DNA (exoDNA) may have
a role in precision medicine, whereby molecular profiling of exoDNA may lead to the identification
of effective therapeutic strategies based on the molecular makeup of a patient’s underlying
cancer from which the exosomes have been released into circulation. Similar in concept to the
use of circulating tumor DNA (ctDNA), exoDNA allows for the profiling of an additional liquid
biopsy compartment, whereby tumor profiling is possible through a minimally invasive approach
compared to more invasive tumor biopsy procedures, thus allowing for repeated biopsy samples
taken throughout disease treatment and progression.
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The presence of chromosomal DNA cargo within exosomes was validated in exosomes
isolated from healthy human plasma and from the culture supernatants of HEK293 human
embryonic kidney cells and K562 human leukemia cells (69). In this study, isolated exosomes
were treated with DNase to ascertain that the isolated genomic DNA presided in the interior,
rather than the exterior of the exosomes, the latter of which would represent the circulating cell
free DNA (cfDNA) fraction. Additionally, as opposed to cfDNA, which exists in the form of
fragmented DNA molecules of ~170bp, exoDNA consisted of high molecular weight DNA.
Numerous groups have since reported the presence of exosomes enriched with long and/or
fragmented genomic DNA of varying sizes from different sources, including plasma, urine, and
pleural effusions, with whole-genome sequencing studies subsequently revealing that exoDNA
covered the entire compendium of human chromosomes without a bias towards particular
regions of the genome (69-72).

The shielding of the genomic DNA by the exosome exterior appears to attenuate DNA
degradation by extracellular DNAses, and enhances the stability of the exoDNA, an observation
that raises the possibility of using tumor-secreted exosomes paired with next generation
sequencing (NGS) as a liquid biopsy platform for comprehensive interrogation of the cancer
genome (73). Additionally, having the ability to profile DNA from different sources in circulation
may allow for characterization of differing biological underpinnings that occur during tumor
progression. In other words, it is generally believed that cfDNA is released in circulation from
cells undergoing active apoptosis or necrosis, versus exoDNA that may be derived from cells
that undergoing rapid proliferation and active biogenesis of exosomes.

A recent study

hypothesizes a potential mechanism of DNA packaging within exosomes involving the
enrichment of Histone H2B proteins within exosomes (74). In other words, these proteins have
a role in identification of foreign or aberrant cytosolic DNA molecules and have been shown to
co-localize with exosomal proteins such as CD63, which is involved in exosome cargo trafficking.
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It is thus thought that exosomes may provide a mechanism for exporting of mutated DNA
molecules out of the cells as a means of self-defense.

Detection of Mutational Signatures in Genomic DNA-Enriched Exosomes
Mutation detection within exoDNA of pancreatic cancer patient plasma initially
demonstrated utility using polymerase chain reaction (PCR) and Sanger sequencing to
determine trademark KRAS and TP53 mutations, known common genetic drivers of pancreatic
cancer (70).

Subsequent reports confirmed that Sanger sequencing detection of mutational

signatures can also be performed in exosomes secreted by prostate cancer cells (75). For
prostate cancer patients, this methodology can be applied not only in excreted urine, but also in
circulation, as high molecular weight exosomal DNA fragments were also identified in the plasma
of prostate cancer patients (75, 76).

Interestingly, the presence of exosomes has been

acknowledged in a range of biological fluids including blood, urine, milk, and saliva, creating
several opportunities for applications that rely on the fluid context, such as the use of exosomes
in the urine for urinary tract malignancies, exosomes in pleural fluids for lung/mesothelial
cancers, or exosomes within the blood for visceral malignancies (77) .

Exosomes as Agents for Early Detection, Diagnosis, and Stratification
In recalcitrant cancers such as pancreatic ductal adenocarcinoma (PDAC), diagnosis
often occurs at a late stage of the disease when the cancer becomes virtually uncurable. This is
typically attributed to the late presentation of disease symptoms and an inability to discern low
volume (early stage) disease. Currently, carbohydrate antigen 19-9 (CA 19-9) is the circulating
tumor marker most commonly used for diagnosis in the clinic. Because CA 19-9 is not elevated
in the early stages of PDAC, and is also present in many benign cases of pancreatitis and biliary
obstruction, it has mostly been used as a prognostic tool to track tumor progression. As a result,
new methodologies with the capacity to detect tumors at an early, treatable stage without the
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direct, invasive sampling of the cancer, are desperately needed to address these types of
aggressive cancers. Noninvasive liquid biopsy strategies involving the isolation of circulating
tumor cells (CTCs) and ctDNA from patient blood to determine the presence of an asymptomatic
cancer have shown promise, but the diagnostic and early detection potential of circulating
exosomal DNA (exoDNA) is just beginning to be understood (42, 44, 78).

As the principal driver mutation, KRAS is near ubiquitous in PDAC, with an estimated
~95% of tumors exhibiting some KRAS mutations (79, 80). This near ubiquitous presence of
KRAS in PDAC tumors, and the fact that it represents one of the first mutations that is acquired
during carcinogenesis, suggests that a strategy for its detection in the context of liquid biopsies
may provide an avenue for early detection and treatment monitoring (81). Using an ultrasensitive
mutation detection methodology known as droplet digital polymerase chain reaction (ddPCR),
Allenson et al demonstrated the feasibility of detecting KRAS mutations in exoDNA from PDAC
patients, and determining the circulating mutant allele frequency (MAF) for the oncogenic allele
amongst a sea of wild type DNA (82). This study demonstrated the ability to detect mutant alleles
in exoDNA obtained from all stages of PDAC, as well as allowing for stratification of patient
survival outcomes based on the KRAS MAF. Notably, mutation detection of exosomal KRAS
(exoKRAS) was seen in 7.4% of age matched healthy controls, 66.7% of localized disease, 80%
of locally advanced disease, and 85% of metastatic PDAC, representing 75.4% sensitivity and
92.6% specificity for exoKRAS as a tumor biomarker for evaluating PDAC. Furthermore, a
patient that tested positive for exoKRAS was 8.17 times more likely to have an early stage cancer
rather than be tumor-free. Interestingly, exoKRAS MAF levels correspond with disease-free
survival in patients with localized disease, where patients with an exoKRAS of >1.0%
experiencing poorer disease free survival, a relationship that the prognostic biomarker CA 19-9
did not illustrate. This suggests that there may be a subpopulation of patients that may require
more aggressive intervention and follow-up.
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In the aforementioned study, it was also notable that exoDNA outperformed ctDNA in the
detection of PDAC, and generated significantly higher detection rates of positivity across all
stages of the disease, but most important in the early stages (resectable stages) of cancer. The
ddPCR analysis of cfDNA revealed mutant cfKRAS detection in 14.8% of healthy controls, 45.5%
of localized disease, 30.8% of locally advanced disease, and 57.9% of metastatic PDAC. A
possible explanation for this discordance is that ctDNA is theorized to be released extensively
into circulation only at the later phases of PDAC, where dying cells becomes more pervasive,
and as a result, may be less effective at pinpointing early stage disease manifestations (83).
Thus, exoDNA, a product of normal biogenesis pathways, may be a promising alternative to
ctDNA for the earlier detection of PDAC. As a cautionary note, mutant KRAS was also found in
healthy individuals (including two independent cohorts from the US and Europe), a phenomenon
that appears to increase with age-related clonal hematopoiesis and/or the likely presence of
KRAS-mutant precursor lesions within the pancreas, GI tract or lung. This finding serves to add
an important caveat to the utility of the current methodology as an early diagnostic tool, and
prevent the phenomenon of “overdiagnosis”. It is thus important to consider limiting such screens
to high-risk populations using current assay technologies, or develop methodologies that may
increase specificity, such as detection of a panel of mutations that represents a higher probability
for an underlying cancer (as opposed to a clinically insignificant precursor lesion).

Genomic Molecular Profiling of Exosomal Cargo
A key component of a precision medicine approach to cancer is the ability to profile the
molecular characteristics of a patient’s underlying cancer. This is particularly difficult for visceral
cancers such as PDAC where attempts at surgical sampling of tumor tissue are inherently
invasive and frequently limited by the obscure tumor location and risk accompanied with surgical
procedure (84). Minimally invasive liquid biopsies have been attractive alternatives to direct
tissue sampling. Investigators have previously used plasma-derived, cfDNA to identify key
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oncogenic “hotspot” drivers (ie. BRAF, KRAS, EGFR) via digital PCR, but the highly fragmented
nature of cfDNA makes applications involving next-generation sequencing (NGS) platforms more
challenging (85-87). Though attempts at using cfDNA for targeted genomic profiling have been
published (and companies such as Foundation Medicine, GRAIL, and Guardant Health are
heavily investing in such cfDA “liquid biopsy” assays), the feasibility of circulating exosomes as
means for tumor profiling and disease monitoring has only just begun to be described.

A recent study sought to determine the efficacy of exosomes in visceral tumor genomic
profiling (72). San Lucas et al isolated circulating exosomes from various bodily fluid sources
including peripheral whole blood and pleural effusions of metastatic PDAC patients.

The

exoDNA extracted from these exosomes contained genomic DNA of high molecular weight,
which was representative of the entire human genome (65%-91% genomic representation on
whole-genome sequencing). The exoDNA isolates further revealed high representation of tumor
fraction ranging from 56%-82%, suggesting that this liquid biopsy compartment may confer an
enriched source of tumor derived material in circulation. This is further emphasized by the high
cancer-derived DNA fraction found in exosomes obtained from a pleural effusion (82%) in the
context of <1% malignant cells on cytospin in the same sample. Whole exome sequencing of
exoDNA further revealed several potentially actionable mutations, including COSMIC (Catalogue
of Somatic Mutations in Cancer) alterations that could be used to monitor tumor genomic
evolution over time, and COSMIC genes that could be addressed through a particular clinical
trial or chemotherapy. Sequencing data of exoDNA also illustrated amplified copy numbers of
major mutational signatures such as KRAS, EGFR, and ERBB2. In a particularly interesting case
demonstrating the potential utility of exoDNA for therapeutic selection, the investigators detected
an unexpected somatic BRCA2 mutation, known to impair homologous recombination, a critical
DNA repair mechanism in actively dividing cells. This patient subsequently achieved a striking
response to a regimen comprising of cisplatin, a crosslinking agent that generates widespread
DNA damage. Although retrospective and correlative in nature, this data suggests that further
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characterization of how mutation detection through exoDNA can impact therapeutic decisionmaking is further warranted.

In a separate study, Castillo et al describe an enrichment methodology to specifically
capture cancer-specific exosomes (CSEs) from the circulation, allowing for the ability to perform
high resolution genomic characterization through the captured cargo (74). The authors identified
a panel of six proteins - CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE and HIST2H2BF that were specifically expressed on the surface of PDAC-derived CSEs (“surfaceome”), and
could be exploited through an immunocapture approach for enriching CSEs. As opposed to
ctDNA, which cannot be specifically captured from the total cfDNA compartment, exosomes have
the added benefit of expressing tumor specific markers that can be used to separate tumor and
normal tissue derived exosomes. This is particularly relevant in the context of those patients
undergoing active therapy where circulating tumor burden can dramatically decrease to the point
of making mutational events in circulation undetectable using current technologies, or in the
context of early detection of an asymptomatic cancer where the volume of CSEs might be
overwhelmed by the complement of normal exosomes. To overcome this limitation, Castillo et
al applied an antibody cocktail through an immunocapture technique that allowed for positive
selection of CSEs, which can be subsequently used for mutation detection. Using this assay,
they achieved an increase in mutation detection from 44% to 73% in non-captured versus
captured exosomes. The authors also demonstrated the utility of this technique in being able to
perform NGS on CSE-derived exoDNA through a molecular barcoding targeted sequencing
approach. In an index case of a patient who initially responded to PARP inhibitor therapy
secondary to a somatic BRCA2 stop-gain mutation, and subsequently progressed, the authors
were able to identify a putative mechanism of resistance through a second splice site mutation
of the same gene, which allowed for reversion of the initial stop-gain (“BRCA2 reversion
mutation”).

This further demonstrates the ability of exosomes to not only detect genomic
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vulnerabilities, but also to provide a means to identify mechanisms of resistance for real-time
precision oncology decision making.

Transcriptomic Characterization of Tumors Through Liquid Biopsies
As a source a highly enriched tumor material, exosomes also contain a milieu of cargo
that can be used for tumor characterization, such as mRNA.

Whereas cfRNA is largely

comprised of highly fragmented circulating RNA transcripts, limiting the molecular assays to
those involved in microRNA detection, RNA within exosomes (exoRNA), provides a source of
long mRNA transcripts that allow for more detailed characterization of tumors through liquid
biopsies. In the study by San Lucas et al, exoRNA allowed for the orthogonal validation of gene
amplifications, as in the case of overexpression of ERBB2 (72). In addition, the benefits of this
transcriptome-based approach may also extend towards the determination of novel cancerspecific fusion transcripts that may otherwise not be apparent from genomic sequencing only.
Further, the identification of expressed cancer-derived neoantigens (both missense mutations
and fusions) may facilitate emerging precision immunotherapies that rely on discovery of such
neoantigens in a patient-specific manner. Ultimately, this may also allow for profiling of the
dynamic changes in the neoantigen repertoire, which may occur from selective pressures and
“antigen editing” that occurs during tumor progression. Through serial monitoring of tumor
associated antigens and how these evolve over time, one can begin to suggest novel therapeutic
approaches relating to ideal immunotherapeutic stratification. Specifically, quantitative estimates
of neoantigen load through liquid biopsies may provide an early surrogate of response to
immunotherapies such as vaccines or engineered T-cell receptors, of which there is currently no
readily available biomarker.

Conclusions
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Next-generation sequencing of circulating exosomes (including enriched CSEs) provides
promising strategies for non-invasive tumor profiling and disease monitoring. Recent data from
many laboratories suggests that exosomes are an important component of liquid biopsies,
facilitating identification of actionable mutations critical to developing patient-tailored precision
treatment regimens. In addition, the ability of exoRNA to profile the tumor transcriptome presents
many new exciting opportunities, such as the discovery of novel neoantigens that may serve as
the basis for emerging adoptive T-cell immunotherapies. This system also exhibits high clinical
relevancy with abridged times from patient blood draw to exosome sequencing and data analysis.
These promising data warrants the further development of exosomes as a complementary
clinical tool in early disease detection, disease monitoring, and therapeutic stratification.
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Chapter 2 – Materials and Methods
Cell lines and culturing
PATC43, PATC66, and PATC92 were established from patient derived tumor xenografts (88).
These lines were maintained in RPMI-1640 medium with 10% FBS. MIAPaCa-2, Pa01C, Pa02C,
Pa03C, Pa04C, Pa07C, Pa08C, Pa09C, Pa021C, and Pa028C are established pancreatic
cancer cell lines from primary or metastatic tissue (10). These lines were maintained in DMEM
medium with 10% FBS. Non-neoplastic cell lines used include HPNE, an hTERT-immortalized
human pancreatic epithelial line; CAF19, an immortalized cancer-associated fibroblast line from
a PDAC patient; and SC2, an immortalized fibroblast line established from non-neoplastic
pancreas tissue (89, 90). CAF19 and SC2 were maintained in DMEM medium with 10% FBS.
HPNE was grown in 75% DMEM without glucose, 25% Medium M3 Base (Incell Corp. Cat#
M300F-500), 5% FBS, 10ng/ml human recombinant EGF, and 5.5mM D-glucose (1g/L).

Exosome isolation from cell lines
PDAC and non-neoplastic pancreas epithelial cell lines were cultured in HYPERflasks in
respective medium (Corning). Upon reaching 70% confluency, cell lines were starved of 10%
FBS for 48 hours and media supernatant was harvested. In summary, 4000mL of media was
centrifuged serially at 1000 RPM for 10 minutes at 4°C, where cell pellets were discarded and
then the supernatant centrifuged at 5000 RPM for 10 minutes at 4 °C to remove cellular debris
(Figure 1). Resultant supernatant was filtered through a 0.22 μm pore filter, then ultracentrifuged
at 154,000g at 4 °C overnight. The resulting pellet was resuspended in 66 ml of PBS with a
subsequent ultracentrifugation step performed at 154,000g at 4 °C for 2 hours. The resulting
exosome pellet was resuspended in 100ul of PBS and harvested for downstream analyses
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Exosome isolation from patient samples
Three 8.5ml Acid Citrate Dextrose tubes (BD) of blood were collected from each patient. The red
blood cells and plasma were separated by centrifuging blood samples at 2500 rpm for 10 minutes
at room temperature. On average, a total of ~11.7ml of plasma was obtain and diluted in PBS to
50mls. The plasma was centrifuged at 1000 rpm for 5 minutes, then the supernatant was
decanted and centrifuged at 5000 rpm for 10 minutes to remove the remaining cellular debris.
The plasma solution was split between 3 ultracentrifuge tubes, diluted in PBS to a maximum
volume of 66ml and spun overnight at 154,000xg. The plasma pellet was washed with PBS and
spun in the ultracentrifuge for 2 more hours at 154,000xg. The supernatant was discarded and
the exosome pellets were collected by resuspending in 600ul of PBS. Exosomes in the “total
exosome control cohort” were processed immediately for DNA isolation using the QIAamp
Circulating Nucleic Acid Kit (Qiagen, Cat# 55114) per the manufacturer’s protocol. Exosomes
samples within the “Captured exosomes” cohort were processed as described below.
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Figure 1: Exosome isolation scheme from cell culture media and human plasma for
downstream analysis

DNA isolation and mutation detection
Cell-free DNA (cfDNA) was isolated using the QIAamp Circulating Nucleic Acid Kit (Qiagen)
according to the manufacturer’s protocol. In selected samples in which cfDNA was not initially
detected, cfDNA was subsequently amplified using the RepliG Cell WGA kit (Qiagen) according
to the manufacturer’s protocol. ExoDNA was isolated using the MagAttract High Molecular
Weight DNA kit (Qiagen) according to the manufacturer’s protocol. DNAase I treatment of
exosomes was performed as previously reported to confirm extraction of DNA from the exosome
compartment and not cfDNA[1]. In select samples in which gene mutations were not initially
detected in exoDNA, whole genome amplification was performed using the RepliG Cell WGA kit
(Qiagen) according to the manufacturer’s protocol.
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Digital PCR
Droplet digital PCR (ddPCR) (QX200; BioRad, Hercules, Calif) was used for highly sensitive
detection of genetic mutations with a multiplex KRAS assay containing G12V, G12D, G12R,
G12C, G12S, G12A, G13D mutant codons. Estimation of false-positive rate (FPR) was first
determined across multiple wells containing KRAS wild type DNA from a healthy individual as
well as a non-template control (NTC). A cutoff of more than 2 droplets in the mutant channel was
determined to be optimal for providing no FPR and classifying a sample as having mutant
molecules. A lower limit of detection (LOD) was then determined of 0.01% MAF (Figure 2).
Subsequently, for each experiment done on clinical samples, wells containing a positive control
and two negative controls were included to determine the absence of contamination and PCR
efficiency of the ddPCR probes in each plate. Positive controls consisted of one of either
pancreatic cell line (Pa04C or Panc1), while the negative controls included a wild-type well of
DNA from a healthy individual and a well with just water as a non-template control. Interpretation

Titration experiment
ddPCR KRAS MAF
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Figure 2 Low limit of detection of KRAS mutations through droplet digital PCR

and analysis of results was done in accordance with BioRad Rare Mutation Detection Best
Practice Guidelines for Droplet Digital PCR. Data was processed using QuantaSoft v.1.6 (BioRad).
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Statistical analyses
Statistical analyses were performed using the R and SAS programming languages. Descriptive
comparisons of study variables used the Fisher’s exact test for categorical data and the Wilcoxon
rank sum test for continuous data. Univariate analyses using Cox proportional hazard models
were performed to examine potential clinical and molecular factors contributing to survival.
Survival curves were generated using the Kaplan-Meier method, and log-rank tests were used
to compare survival curves. Clinical outcomes were established as defined by the National
Cancer Institute (91). KRAS sensitivity and specificity was determined as related to the patient’s
cancer status.

Exosome Protein Fractionation
Exosome surface and cargo proteins were isolated from the same sample (Figure 3). To isolate
exosome surface from cargo proteins, the exosome pellet was biotinylated with 5 ml of 1 mg/ml
of Sulfo-NHS-SS-BIOTIN (Pierce) in PBS for 30 min at 4 °C. The residual biotinylation reagent
was quenched with 10mL of 100 mM lysine in cold PBS for 15 min at 4 °C. Biotinylated exosomes
were recovered through ON ultracentrifugation at 100,000 g. Biotinylated exosomes were then
sonicated in 2 ml of 4M Urea, 3% IsoPropanol, 20 mM Tris, 2% OG and protease inhibitors
(complete protease inhibitor cocktail, Roche Diagnostics) followed by centrifugation at 20,000 g
at 4 °C for 30 min. Biotinylated proteins were isolated by affinity chromatography using 2 ml of
UltraLink Immobilized Neutravidin (Pierce) according to the manufacturer’s instructions. Proteins
bound to the column were recovered by reduction of the biotinylation reagent with 1 ml of a
solution containing 65 µmol of DTT and 2% (w/v) OG detergent overnight at 4 ºC and referred to
as exosome surface proteins. Proteins not bound to the column (flow through) were also collected
and named cargo proteins. Exosome surface and cargo proteins were fractionated by reversedphase chromatography, using the same amount of proteins across different samples for a given
31

exosome compartment. All three extracts were reduced by DTT and alkylated with
iodoacetamide prior to chromatography. Separation were performed in an off-line 1100 series
HPLC system (Shimadzu) with reversed phase column (4.6 mm ID × 150 mm length, Column
Technology Inc) at 2.7 ml/min using a linear gradient of 10 to 80% of organic solvent over 30 min
run. Solvent system used was: aqueous solvent – 5% acetonitrile / 95% water / 0.1% of
trifluoroacetic acid; organic solvent – 75% acetonitrile / 15% isopropanol / 10% water / 0.095%

Figure 3: Schematic representation of surface exosome protein extraction

trifluoroacetic acid. Fractions were collected at a rate of 3 fractions per minute.
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Mass Spectrometry Analysis
Each fraction from the reverse phase chromatography were in-solution digested overnight at 37
°C with 400 ng of trypsin. The resulting trypsinized fractions were pooled into 4 to 10 pools based
on chromatographic features. Pools were individually analyzed by LC-MS/MS. LC-HDMSE data
were acquired in resolution mode with SYNAPT G2-S using Waters Masslynx (version 4.1, SCN
851). The capillary voltage was set to 2.80 kV, sampling cone voltage to 30 V, source offset to
30 V, and source temperature to 100°C. Mobility utilized high-purity N2 as the drift gas in the IMS
TriWave cell. Pressures in the helium cell, Trap cell, IMS TriWave cell, and Transfer cell were
4.50 mbar, 2.47e-2 mbar, 2.90 mbar, and 2.53e-3 mbar, respectively. IMS wave velocity was
600 m/s, helium cell DC 50 V, Trap DC bias 45 V, IMS TriWave DC bias V, and IMS wave delay
1000 μs. The mass spectrometer was operated in V-mode with a typical resolving power of at
least 20,000. All analyses were performed using positive mode ESI using a NanoLockSpray
source. The lock mass channel was sampled every 60s. The mass spectrometer was calibrated
with a [Glu1] fibrinopeptide solution (300 fmol/µL) delivered through the reference sprayer of the
NanoLockSpray source. Accurate mass LC-HDMSE data were collected in an alternating, low
energy (MS) and high energy (MSE) mode of acquisition with mass scan range from m/z 50 to
1800. The spectral acquisition time in each mode was 1.0 s with a 0.1-s inter-scan delay. In low
energy HDMS mode, data were collected at constant collision energy of 2 eV in both Trap cell
and Transfer cell. In high energy HDMSE mode, the collision energy was ramped from 25 to 55
eV in the Transfer cell only. The RF applied to the quadrupole mass analyzer was adjusted such
that ions from m/z 300 to 2000 was efficiently transmitted, ensuring that any ions observed in the
LC-HDMSE data less than m/z 300 arised from dissociations in the Transfer collision cell. The
acquired LC-HDMSE data were processed and searched against protein knowledge database
(UniProt) through ProteinLynx Global Server (PLGS, Waters Company) with 4% False Discovery
rate. Each dataset was normalized to the total number of spectral counts of the each
compartment.
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PDAC specific “surfaceome” profiling of exosomes
Proteins that were expressed at a higher prevalence in normal samples compared to tumor
samples in ExoCarta were filtered out, resulting in 139 PDAC-specific exosomal surface protein
markers (corresponding to 103 genes; Supplementary table 2). Subsequently, we identified
three additional “borderline” proteins in our initial PDAC-specific exosomal marker list that did not
meet these filtering criteria: CD151, UBA52 and HIST2H2BF, but have been previously described
in the context of exosomes and tumorigenesis (CD151) (92), were found in a high proportion of
cancer cell lines (11/13) even though being found in one non-neoplastic line (UBA52), or have
biological and complementary relevance to other identified candidates HIST2H2BF (93). We then
manually selected candidates for pull-down that were collectively represented across all of the
PDAC cell lines and prioritized validation based on biological rationale and availability of targeting
antibodies

Captured Exosomes/Pulldown
Antibody coating of beads was performed with 3ul of Aldehyde/Sulfate latex beads resuspended
in 500ul PBS and incubated with 200ug of primary antibody anti-Histone H2B (Mouse monoclonal
mAbcam 52484, Abcam), Anti-CD151 (Mouse monoclonal 11G5a, AB33315, Abcam),

anti-

LGALS3BP (Mouse monoclonal 3G8, AB123921, Abcam), anti Epcam, (Mouse monoclonal
AUA1, AB20160, Abcam) or anti Claudin-4 (Mouse monoclonal 3E2C1, Thermo-Scientific) per
1ml of beads and incubated overnight at 4C on a Eppendorf ThermoMixer® C. The following day,
500ul of 1% BSA was added and incubated for 30 minutes. Coated beads were then pelleted
down through centrifugation at 12,000RPM for 5 minutes. Pellet was resuspended in 1ml of
1%BSA 100mM Glycine solution for 30 minutes followed by centrifugation at 12,000 RPM for 5
minutes. Pellet was resuspended in 200ul of 1%BSA and incubated with samples of patient
derived exosomes overnight at 4C. Exosome coated beads were centrifuged at 12,000 RPM for
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5 minutes and washed 3 times with 800ul of 1% BSA. For flow cytometry analysis, resulting
exosome attached beads were stained with PE conjugated Mouse Anti-Human CD63 (BD
Bioscience, #556020). Isotype control was stained by Simultest IgG2a/IgG1 (BD Bioscience,
#340394).

Flow cytometry was performed on an Accuri C6 System (BD Bioscience) and

analyzed on Flow Jo software. For DNA isolation, washed pellet was resuspended in appropriate
lysis buffer for DNA isolation using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Cat# 55114)
per the manufacturer’s protocol.

Electron microscopy
Microscopy imaging was performed in the High Resolution Electron Microscopy Facility at MD
Anderson. In summary, exosome-diluted aliquots were fixed in Formaldehyde/Glutaraldehyde,
2.5% each in 0.1M Sodium Cacodylate Buffer, pH 7.4 for 15 minutes. For TEM imaging, samples
were placed on 100 mesh carbon coated, formvar coated copper grids treated with poly-l-lysine
for approximately 1 hour. Samples were then negatively stained with Millipore-filtered aqueous
1% uranyl acetate for 1 min. Stain was blotted dry from the grids with filter paper and samples
were allowed to dry. Samples were then examined in a JEM 1010 transmission electron
microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating voltage of 80 Kv. Digital images
were obtained using the AMT Imaging System (Advanced Microscopy Techniques Corp.,
Danvers, MA). For SEM images, fixed samples were placed on round coverslips treated with
poly-l-lysine for approximately 1 hour, washed with 0.1 M cacodylate buffer, pH 7.3, post fixed
with 1% cacodylate buffered osmium tetroxide, washed with 0.1M cacodylate buffer, then in
distilled water. Afterwards, the samples were sequentially treated with Millipore-filtered 1%
aqueous tannic acid, washed in distilled water, treated with Millipore-filtered 1% aqueous uranyl
acetate, then rinsed thoroughly with distilled water. The samples were dehydrated with a graded
series of increasing concentrations of ethanol, then transferred to graded series of increasing
concentrations of hexamethyldisilazane (HMDS) and air dried overnight. Samples on coverslips
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were mounted on to double-stick carbon tabs (Ted Pella. Inc., Redding, CA), which have been
previously mounted on to aluminum specimen mounts (Electron Microscopy Sciences, Ft.
Washington, PA). The samples were then coated under vacuum using a Balzer MED 010
evaporator (Technotrade International, Manchester, NH) with platinum alloy for a thickness of 25
nm., then immediately flash carbon coated under vacuum. The samples were transferred to a
desiccator for examination at a later date. Samples were examined in a JSM-5910 scanning
electron microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating voltage of 5 kV.

Exosomes size distribution measurement
Exosomes were resuspended in PBS and serially diluted to the optimum dynamic range of the
Zetaview nanoparticle analyzer (Particle Metrix, Diessen, Germany) for measurement of size and
particle density. Observed and tracked particles were incorporated into size distribution
calculations according to the particles’ Brownian motion. The diffusion constant is then calculated
and transferred into a size histogram via the Einstein Stokes relation between diffusion constant
and particle size. For calculation of exosome concentrations, exosome yield was extracted by
analyzing the Zetaview raw data and taking into account input plasma, dilution factor, and
exosome volume.

Flow cytometry
Plasma exosomes were captured using the CD63+ Dynabead exosomes isolation kit according
to manufacturer's instructions (Invitrogen, Life Technologies #10606D). Flow analysis of patient
exosomes bound to Dynabeads conjugated with antibody was done according to the
manufacturer's protocol. Briefly, 10 µl of exosomes were incubated with 90 µl of CD63+
Dynabeads overnight at 4°C. A Dynabead magnet was then used to positively select for bound
exosomes, which were then stained with PE Mouse Anti-Human CD63 (BD Bioscience,
#556020). Isotype control was stained by Simultest IgG2a/IgG1 (BD Bioscience, #340394). Flow
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cytometry was performed on an Accuri C6 System (BD Bioscience) and analyzed on Flow Jo
software (v.10.0.7).

Western Blot Analyses
Proteins extracted from the human cell lines SC2, CAF-19, PA01C, Pa03C and Pa04C and
exosomes from the respective cell lines were used to examine different protein markers.
Exosomes were lysed with RIPA buffer 1x (Sigma-Aldrich) and 1x Protease Inhibitor Cocktails
(Sigma-Aldrich). Sample loading was normalized according to Bradford relative protein
quantification. The proteins were mixed NuPAGE® LDS Sample Buffer (4X) and 10x NuPAGE®
Sample Reducing Agent (Invitrogen) to a final concentration of 20ug(per sample), then heated
at 70°C for 10 min and loaded onto a 1.0 mm × 10 well 4–12% Tris-Glycine gel (Novex) and thus
the proteins were separated following an electrophoretic gradient across polyacrylamide gels.
The gel was run under denaturing conditions at 180 V for 1h and then transferred nitrocellulose
membrane (Bio-Rad) using the Trans-Blot® Turbo™ Transfer System with and 1x transfer buffer
10% with ethanol at 1.3Ampers - 25Volts – 8Minutes. The protein blot was blocked for 1 h at
room temperature with 5% non-fat dry milk in PBS/0.05% Tween and incubated overnight at 4
°C with the following primary antibodies 1:1000 anti-Histone H2B (Mouse monoclonal mAbcam
52484, Abcam), 1:1000 Anti-CD151 (Mouse monoclonal 11G5a, AB33315, Abcam), 1:1000 antiLGALS3BP (Mouse monoclonal 3G8, AB123921, Abcam), 1:1000 anti CD63 (Mouse monoclonal
TS63, AB59479, Abcam), 1:1000 anti Epcam, (Mouse monoclonal AUA1, AB20160, Abcam),
1:1000 anti GPC1 (Rabbit polyclonal, PA5-24972 Thermo-Scientific), 1:1000 anti Claudin-4
(Mouse monoclonal 3E2C1, Thermo-Scientific), 1:1000 anti GAPDH (Rabbit monoclonal
EPR16884, AB181603, Abcam), 1:1000 anti TSG-101 (Mouse monoclonal 4A10, AB83, Abcam).
Afterwards, secondary antibody goat anti-rabbit IgG-HRP (sc-2004, Santa Cruz) or secondary
antibody goat anti-mouse IgG-HRP (sc-2005, Santa Cruz) were used. The membranes were
incubated for 1 h at room temperature. Membranes were cleared after antibody incubations in
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an orbital shaker four times at 5-min intervals with PBS 0.05% Tween20. Clarity™ Western ECL
substrate Chemiluminescence kit was utilized on the next step; Membranes were developed for
10 seconds to 1 min and the picture was analyzed.

Whole exome, genome, and transcriptomic sequencing
For each patient we performed whole genome, exome and transcriptome sequencing on their
exoDNA and exosomal mRNA. We also performed exome sequencing of the peripheral blood
mononuclear cells (PBMCs) for each patient for use as a reference in determining the somatic
status of identified events.

DNA was captured for exome sequencing using the Agilent

SureSelect Clinical Exome Kit and subsequently sequenced on an Illumina HiSeq 2500 by the
Avera Institute for Human Genetics to a mean sequencing depth of 490, 256 and 133 for LBx0103 exoDNA and 60x for PBMC DNA using 100-base paired-end reads. Custom bioinformatics
pipelines were applied to raw Illumina HiSeq reads for analyzing the patient exomes, including
the metastatic lung tissue exome sequencing reads provided by Dr. Arul Chinnaiyan at the
University of Michigan.

Briefly, for DNA sequencing read alignment, the Burrows-Wheeler

Aligner (BWA) (94) is used for initial alignment to the human genome reference build hg19, Picard
is used for manipulating and preprocessing Sequence Alignment/Map (SAM) format files (95),
and the Genome Analysis Toolkit (GATK) (96) is used to perform local realignment of sequencing
reads. For the metastatic lung RNA-seq (reads provided by Dr. Arul Chinnaiyan) and the
exoRNA, cDNA reads were aligned using RNA-Seq by Expectation-Maximization (RSEM) (97).
LBx01 cDNA alignment resulted in 1101228222 mapped reads. LBx02 had 118429984 mapped
reads, and LBx03 had 274391009 mapped reads.

Identification of somatic events
Given the aligned reads, MuTect was run on exosome and PBMC sample pairs for the sensitive
detection of point mutations (98). In a similar analysis, the metastatic lung tissue exome from
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LBx01 was compared with the corresponding PBMC exome. IndelLocator was used to identify
small somatic insertions and deletions using similar “tumor/normal” paired analyses (96).
Somatic mutation reports were generated and filtered using Variant Tools (99), which annotated
our mutations with information from COSMIC (100), dbNSFP (101), the 1000 Genomes Project
(102), the Exome Sequencing Project (103), ClinVar (104) and potentially actionable gene lists
from Jones et al (105) and MD Anderson Cancer Center (unpublished). Gene fusion events
were detected in RNA-sequencing data using ChimeraScan (106).

Filtering and annotation of somatic mutation calls
Using a probabilistic model that is dependent on read quality, sequence context and allele
counts, MuTect provides a PASS or REJECT status for each putative mutation. We filtered out
point mutations with non-PASS statuses. To help control for false-positives point mutations and
indels, we required a minimum read depth of 20x in the germline and exoDNA to make a positive
call. Any mutation that had at least 1 mutant read in the normal DNA was filtered out. We
explicitly attempted to filter out exoDNA false-positive mutations that might be germline variants
missed in the PBMC data (or common polymorphisms) by cross-checking candidate mutations
against population variant annotations (including the 1000 Genomes project and the Exome
Sequencing Project), where we removed mutation calls seen in 1% or more of the samples in
these population-level projects.

We visually verified nonsynonymous mutations using the

Integrated Genomics Viewer (IGV) (107). For each patient, we performed visual verification on
events by inspecting the sequencing reads at each candidate mutation site across all of that
patient’s samples. These QC filters were relaxed in cases where the mutation was seen with
high frequency (at least 10 times) in the COSMIC database. The set of mutations used for
estimation of mutation rates include those point mutations that passed this filtering step with the
additional removal of mutations with less than a 5% mutant allele frequency to try to globally
control for false positives.
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Potentially clinical somatic events
Only nonsynonymous SNV, stopgain and frameshift insertions and deletions in exoDNA (called
from exome sequencing) were considered for potential actionability. Mutations residing in a list
of actionable genes, an aggregate list of actionable genes composed of those from Jones et al
2015 (105) and a list compiled from MD Anderson experts were annotated as potentially
actionable. To help control for false positives, from the remaining mutations with a 5% mutation
allele frequency or less, potential actionable mutations had to be seen in COSMIC or verified in
the patient exosomal mRNA or exoDNA (through whole genome sequencing) to be considered
as a candidate for potential actionability.

Identification of cancer-associated copy number events
Copy-number events were called using control-FREEC 7.2 on whole genome sequencing data
with unpaired samples (108). A list of cancer-associated genes was downloaded from the
Cancer Gene Census from the COSMIC database. Coordinates for each gene for the start and
end of transcription were retrieved from the UCSC Genome Browser (hg19) (109).

We

intersected the coordinates of the copy-number events with the maia transcription coordinates of
the cancer-associated genes and assigned the estimated copy-number (from control-FREEC) to
each gene that had overlapping coordinates with the event. The data were subsequently
visualized using a custom R script.

Estimation of tumor fraction and ploidy of exoDNA
We analyzed paired exome data from exoDNA and PBMC DNA using Sequenza 2.1.0 to
estimate tumor fractions and ploidy (110). Sequenza is an implementation of a probabilistic
model that incorporates average depth ratios between tumor and normal samples and allele
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frequencies at germline heterozygous positions to segment DNA into copy number variant
regions while estimating tumor cellularity and ploidy. The log posterior probability (LPP) of the
observed copy number and allele frequencies are calculated by Sequenza for a range of
candidate ploidy and cellularity values. The point estimate is given for the ploidy and cellularity
with maximum LPP. The 95% confidence range is a region of point estimates with a total
posterior probability of greater than 0.95. In the liquid biopsy context, exoDNA represents the
tumor sample and PBMC DNA the normal sample in the Sequenza configuration, and for
interpretation we use the tumor cellularity estimate as an estimate of the tumor fraction in the
exoDNA. To run Sequenza, we first generated a GC content profile for the human genome hg19
using a window size of 50 base pairs. Then for each patient, we generated depth profiles for
both the exoDNA and the PBMC DNA using the mpileup command of SamTools 0.1.19 (95) for
subsequent processing using Sequenza.

Gene quantification and fusion detection
RNA-seq reads were aligned and quantified using RSEM (97). Expressed transcripts were
checked for overrepresentation of GO terms and biological pathways using the DAVID
Bioinformatics resource (111). The enrichment program is limited to 3000 genes as a maximum,
thus, for the plasma exosomes samples, the expressed transcripts were limited to those
expressed at larger than 10 TPM. For the pleural effusion sample, transcripts expressed at 50
TPM or more were included. This allowed for the approximately top 3000 expressed transcripts
for each sample to be included in the enrichment analyses. The TPM threshold for the pleural
effusion exosomes is higher because it was more deeply sequenced compared to the plasma
samples. Gene fusions were called using ChimeraScan 0.4.6 on RNA-sequence data (106). The
reference transcriptome (UCSC known genes) was downloaded from the chimerascan download
site (http://chimerascan.googlecode.com/files). Only those events in the plasma samples with at
least 10 read pairs (and 20 read pairs in the pleural effusion sample) were included as candidate
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fusion events. Again, because of the deeper sequencing of the pleural effusion sample, the
threshold used was higher.

Mutation signatures
We characterized mutational signatures using 6 base substitutions (i.e., C>A, C>G, C>T, T>A,
T>C, and T>G) and their 5′ and 3′ bases adjacent to the mutation site, generating 96
combinations of substitutions.

Coordinates and base substitutions for each sample for all

mutations were fed into a custom R script that utilizes the SomaticSignatures package to retrieve
adjacent bases from a genome reference for each mutation (112). Previous studies have
identified existing mutational signatures across various types of cancers, which have since been
included in the COSMIC database (100, 113). We downloaded 30 mutation signatures from the
COSMIC database and visually assessed similarities of pancreatic and lung cancer signatures
with our signatures.

Next generation sequencing with molecular barcodes
Illumina NGS libraries were prepared from enriched plasma derived exosomal DNA and genomic
DNA. A total of 10-80ng of DNA was used for library construction through the QIAseq Targeted
DNA Panel (Qiagen, Cat# DHS-3501Z) which employs a molecular barcoding approach. First,
genomic DNA samples were fragmented, end repaired and A-tailed. The DNA fragments were
then ligated at their 5’ ends with Illumina adapters containing a 12-bp Unique Molecular Index
(UMI) and sample index. These fragments underwent target enrichment PCR - with 11,311 genespecific primers and one universal forward primer complementary to the adapter sequence.
Afterwards, the library is further amplified through universal PCR.
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Bioinformatics with molecular barcodes
The 12-bp barcode provides a possibility of 16,777,216 unique indexes. After mapping to the 275
genes in the QIAseq Targeted DNA panel there is sufficient entropy that the chances of overlap
in of both barcode and template start/stop locations is negligible. Post-amplification, the reads
are grouped according to loci and barcodes. The duplicates are then condensed into ‘Super
Reads’ based on the consensus sequence of each barcode. The selection of this consensus
sequence removes a majority of amplification and sequencing errors.
The Illumina sequencing data was analyzed through Qiagen’s Biomedical Genomics Workbench.
The raw output data was initially processed through the standalone workflow ‘Prepare Raw Data’
to trim any remnants of the Nextera Trim Adapters. Post-trimming, the reads were run through
the ‘QIAseq DNA V3 Panel Analysis’ ready-to-use Workflow. This workflow employs the following
steps: First, PCR adapters are trimmed before the sequences are annotated with their UMI’s.
The sequences are then mapped to a reference using BWA-MEM (114) before being grouped
according to their UMI’s. These groups are then used to create ‘Super Reads’ which are further
processed to remove ligation artifacts and identify any structural variants. Then, these reads
undergo local realignment using the Smith-Waterman algorithm before a primer trimming step.
Finally, a low frequency variant detection workflow is utilized to identify variants using smCounter,
a variant caller based on a posterior Bayesian probabilistic model (115).
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Chapter 3 – Liquid biopsies for detection of early stage pancreatic cancer

With permission this chapter is based upon “Allenson, K., J. Castillo, F. A. San Lucas, G.
Scelo, D. U. Kim, V. Bernard, G. Davis, T. Kumar, M. Katz, M. J. Overman, L. Foretova, E.
Fabianova, I. Holcatova, V. Janout, F. Meric-Bernstam, P. Gascoyne, I. Wistuba, G.
Varadhachary, P. Brennan, S. Hanash, D. Li, A. Maitra, and H. Alvarez. 2017. High prevalence
of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer
patients. Annals of oncology : official journal of the European Society for Medical Oncology /
ESMO 28: 741-747”
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) composes 85% of all pancreatic malignancies and is
associated with a dismal 5-year survival of 6% (116, 117). While cancer prevention initiatives
and advances in targeted therapies have produced tangible survival improvements in breast,
colon, and lung cancers, long-term PDAC survival remains poor and the nature of the disease
does not readily present opportunities for screening and early detection (118-123). Under the
best of circumstances, resection of early stage disease at experienced and high-volume centers
improves 5-year survival to only 24-29% (117, 124-126).

Given the aggressive and recalcitrant clinical course of pancreatic cancer, many efforts have
focused on identifying novel protein, DNA or RNA biomarkers to serve as a means for early
detection or prognostic stratification (127). Blood-based liquid biopsy is particularly attractive in
the context of PDAC, as the primary tumor itself is not routinely accessible in its retroperitoneal
location, and sampling of the tissue is not without morbidity. Circulating tumor DNA and KRAS
genetic mutations as a surrogate for PDAC-specific genetic material has been previously studied
(128-136), and a study by Bettegowda et al, using a bead-based ultrasensitive PCR assay,
demonstrated 48% and 77% detection rates for patients with early and late stage tumors,
respectively (42).

Other reservoirs of proteins, DNA, and RNA have recently been identified in the form of
microvesicles termed exosomes (72, 137, 138).

Exosomes are 40-150nm lipid bilayer

membrane bound particles derived from specific biogenesis pathways within cells and accessible
within the plasma of the circulating peripheral blood (139). Biologically, exosomes have been
shown to be capable of intercellular communication and modulation of the tumor
microenvironment (67, 140). Perhaps more importantly, it is believed that the contents contained
within these particles remains distinct from the remainder of the peripheral blood and thus, might
represent an enrichment of tumor-specific genomic material (72, 137).

While many have
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commented on the utility of “circulating tumor” or “cell-free” DNA (cfDNA) in the context of liquid
biopsy for cancer, here we tested the potential for exosome-derived DNA (exoDNA) to represent
an additional blood-based compartment which may be complementary to cfDNA in the diagnosis
and therapeutic stratification of patients with pancreatic cancer.
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Study populations
Discovery cohort
Whole blood samples were collected at MD Anderson Cancer Center (MDACC) through informed
consent following institutional review board (IRB) approval (PA14-0552). Patients with all stages
of pancreatic cancer were included in the study. Healthy control samples were obtained from
volunteers in the clinic waiting rooms, and for the most part, are relatives of the patients.
Demographic information and personal medical history was collected from these volunteers, but
samples were de-identified after collection, so follow-up of these volunteers was not possible.
Individuals with diabetes, a history of pancreatitis, or a family history of pancreatic cancer were
excluded from the discovery cohort. Whole blood was collected in green top (Sodium Heparin,
BD Vacutainer) tubes. Blood samples were centrifuged at 2500xG for 10 minutes for plasma
isolation and then stored at -80 degree until the time of exosome isolation. Samples were
collected between 2003 and 2010, and between 0.9 and 1.5ml of plasma were available per
patient for both cfDNA and exoDNA analysis. Medical records were queried for the American
Joint Committee on Cancer staging, treatment status, and clinical outcomes.

Staging

considerations were supplemented with National Comprehensive Cancer Network guidelines
with regard to borderline-resectable tumors. A total of 68 patients with PDAC of all clinical stages,
an additional 20 PDAC patients initially staged with localized disease, with blood drawn after
resection for curative intent, and 54 age-matched healthy controls were included in this cohort.

Validation cohort
A total of 39 early stage PDAC patients and 82 age-matched healthy controls were recruited
through an International Agency for Research on Cancer (IARC) case-control study coordinated
in the Czech Republic and Slovakia following informed consent. Researchers were blinded to
the cancer-status of the clinical samples at the time of processing and data analysis. Peripheral
blood was collected in EDTA tubes at the time of consent and processed as rapidly as possible.
Blood samples were centrifuged at 2000xG for 10 minutes for plasma isolation and then stored
47

at -80 degree until the time of exosome isolation, where 200ul of plasma were available for
exoDNA analysis.

Results

Exosome size and concentration
The presence of extracellular vesicles in exosome isolations was confirmed by means of
Zetaview nanoparticle tracking analysis, western blot for exosomal markers, and scanning and
transmission electron microscopy, with the latter in selected samples (Figure 4). Average
particle size was greater among patients with PDAC compared to healthy controls. Further,
average particle size was observed to be greater with more advanced disease (Figure 4B),
particularly, those particles that were between 141 to 220 nm (Figure 4C).

Exosome

concentration was defined as number of exosomes per mL plasma. A cutoff value of 5.0 x 10^9
exosomes was identified through this discovery cohort and found to be associated with overall
survival for both localized and metastatic patients, with a higher exosome concentration
predicting worse survival (Figures 5B and 5C). Localized pre-surgical patients with less than
5.0 x 10^9 exosomes per mL plasma had a median survival of 1040 days compared to 421 days
for those with higher exosome concentrations (P=0.047). Similarly, metastatic patients with less
than 5.0 x 10^9 exosomes per mL plasma had a median survival of 479 days compared to 97
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(P=0.015).

Figure 4: Profiling of exosomal physical characteristics
A. Transmisison and scanning electron microscopy of exosomes demonstrates a bilipid
membrane falling within the size range of a define exosome. B, C. Average particle size oserved
based on Zetaview nanoparticle tracking analysis. D. Flow cytrometry demonstrating presence
of known surface exosome marker, CD63, compared to isotype control. E. Western blot analysis
demonstrates expression of known exosomal markers in exosomes isolated from all patient
populations.
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Figure 5: Liquid biopsy Kaplan-Meier curves
(A) Stratification of exoKRAS at a mutant allele frequency of 1% was associated with disease
free survival in patients with localized disease who were treatment naïve at the time of blood draw
(n = 13) with a median survival of 441 days compared to 127 days (P = 0.031). Two treatment
naïve patients with no KRAS mutant droplets were excluded from this survival analysis to account
for the possibility that they have a KRAS mutation that is not a target of the KRAS multiplex

ddPCR kit used. (B and C) Exosome concentration of 5 × 109 per ml of plasma was associated
with overall survival in treatment naïve blood draws in patients with (B) localized disease
(n = 15, median survival 616 versus 233 days, P = 0.048) and (C) metastatic disease
(n = 12, median survival 479 versus 97 days, P = 0.015).
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Liquid biopsy detects exoDNA KRAS mutants by digital PCR
In the discovery cohort, ddPCR analysis of exoDNA detected KRAS mutations in 66.7% (22/33),
80% (12/15) and 85% (17/20) of localized, locally advanced, and metastatic PDAC patients,
respectively, and in 7.4% (4/54) of controls (Table 1). For predicting PDAC status, the resultant
sensitivity and specificity are 75.4% and 92.6% respectively. Positive mutant KRAS status from
exoDNA was significantly associated with early stage PDAC when comparing patients with
localized disease to healthy individuals (Fisher’s exact test P<0.001), where an individual with
positive KRAS status is 8.17 times (95% CI: 2.46 to 35.58) more likely to have early stage
pancreatic cancer than to be cancer free. Further, compared to localized pre-resected patients
with a mutant KRAS detection rate of 66.7%, in a similar cohort of 20 localized PDAC patients
with blood sampled after resection, mutant detection rate was much lower at 5%. Mutant KRAS
status was significantly associated with pre-resection blood sampling (Fisher’s exact test,
P<0.001). Of note, healthy controls had a mutant detection rate of 7.4% (4/54). KRAS mutant
status in the healthy controls was associated with increased age (mean age of 75 years in mutant
KRAS individuals versus 64 years in wild-type KRAS individuals; Wilcoxon rank sum test
P=0.004).
Table 3: Liquid biopsy mutant call rates among patient populations
cfKRAS mutant call rate
(%)

exoKRAS mutant call rate
(%)

Healthy

8/54 (14.8)

4/54 (7.4)

Localized

15/33 (45.5)

22/33 (66.7)

0/20 (0)

1/20 (5)

4/13 (30.8)

12/15 (80)

Stage of disease
Discovery cohort

Localized
postsurgical
Locally advanced
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cfKRAS mutant call rate
(%)

exoKRAS mutant call rate
(%)

11/19 (57.9)

17/20 (85)

Healthy

–

17/82 (20.7)

Localized

–

17/39 (43.6)

Stage of disease
Metastatic
Validation cohort

In the validation cohort, 44% (17/39) of early stage pancreatic cancer patients tested positive for
KRAS compared to 20% (17/82) of healthy individuals, confirming that KRAS positivity is
associated with pancreatic cancer (Fisher's exact test, P=0.0163). An individual with KRAS
positivity was 2.96 times (95% CI: 1.29 to 6.76) more likely to have pancreatic cancer than to be
healthy. Unlike with the discovery cohort, no association of age with mutant exoKRAS status
was found in the healthy controls.

Mean KRAS mutation allele frequencies were higher in metastatic compared to localized
samples (mean of 10.09% versus 2.7% respectively; Wilcoxon rank sum test P=0.0109).

Stratification of localized patients based on a pre-surgery exoKRAS MAF threshold of 1% was
associated with disease-free survival following resection, (Figure 2A), with a median diseasefree time of 441 vs 127 days for patients with less than 1% MAF compared to those with more
than 1% MAF (P=0.031; Figure 2A). In addition, greater than a 1% MAF was a significant risk
factor impacting disease-free survival (RR, 4.68; 95% CI, 1.014-21.61).

While a slight, yet

statistically significant positive correlation existed between KRAS MAF and CA19-9 levels
(P=0.019, r=0.303), only KRAS MAF was associated with disease-free survival. Cox proportional
hazard analyses were also performed on locally advanced and metastatic patients but no clinical
factors were found to be significantly associated with overall or progression-free survival.
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Performance of cfDNA in liquid biopsy
In the discovery cohort, mutant cfKRAS was detected in 14.8% (8/54), 45.5% (15/33), 30.8%
(4/13), and 57.9% (11/19) of healthy controls, localized, locally advanced, and metastatic
patients. Of these positive cfDNA calls respectively, 12.5% (1/8), 73.3% (11/15), 100% (4/4) and
100% (11/11) were also called positive through exoDNA. As opposed to the exoDNA results,
KRAS positive status in healthy control cfDNA was not associated with increasing age (data not
shown). In the metastatic group, the presence of mutant KRAS cfDNA suggested worse overall
survival (median survival of 115 days compared to 506 days for mutant KRAS negative patients),
but this was not statistically significant (P=0.107).

Discussion:
Exosomes, which have been shown to harbor DNA (70, 72), are the product of specific
biogenesis pathways and are shed from viable cells by the tens of millions into circulation.
Conversely, traditional cfDNA is derived from apoptosis and necrosis of tumor cells, which are
characteristic of later stage disease (141). It may thus be possible that exoDNA is a significant
contributor of the DNA in circulation in patients of earlier clinical stage, before cell death and
tumor necrosis begin to occur. In this context, the origin of the circulating DNAs may explain why
the detection rate for early stage patients in this study was slightly higher with exoDNA than that
previously described for cfDNA, but also why the identification of late stage patients was
concordant (42).

Most encouraging is the observation of a precipitously lower detection rate in the localized pre
and post-resection cohorts, from 66% to 5%. With mutant KRAS being a surrogate for tumorspecific DNA, and resection for curative intent aimed at removing the entirety of the localized
disease, pre- and post- procedure liquid biopsies may have utility in determining the early
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success of resection. It is important to mention though, that the lower KRAS detection may be
an overall marker of response to any therapy, and not just surgery alone. We are unable to draw
such conclusions from this data set as time points before and after other treatment modalities
are not available for our cohorts.

In this study, exoKRAS mutant allele frequency, but not CA19-9, was associated with disease
free survival in localized disease. Whereas presence or absence of cfDNA and overall amount
of DNA has previously been used for stratification, we did not identify such a clinical correlation.
In a tumor where oncogenic KRAS gene mutations are believed to be near ubiquitous, to the
best of our knowledge, this is the first time KRAS mutant allele frequency in exoDNA has been
used for prognostic stratification. While a 1% mutant KRAS fractional abundance was identified
in our discovery cohort as being informative towards disease-free survival, further validation is
warranted for any such proposed cancer biomarker (142).

CfDNA was detected between 30.8-57.9% across stages, which is concordant with the findings
of earlier studies (42). No studies to date have described the detection rate of KRAS mutant
alleles within exosomes across a series of PDAC patients across all stages, nor compared these
directly with cfDNA. For this reason, we performed a parallel analysis of liquid biopsy for cfDNA
KRAS mutations from plasma samples from the same patients to serve as a comparison, in
addition to historical cfDNA detection rates in the literature. In our study, rates of detection of
KRAS mutants in exosomes were superior to cfDNA across all stages. Of particular interest is
our finding that exoDNA revealed a greater detection of patients with localized disease than
previously observed using a highly sensitive method of detection (42). Validation is warranted,
but this finding has potential ramifications for liquid biopsy based diagnostics, especially in
tumors where specific mutant detection yields the opportunity for treatment with targeted therapy.
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Identification of KRAS mutations in 7.4% of exoDNA and 14.8% of cfDNA healthy controls in the
discovery cohort and in 20.7% in the exoDNA of the validation cohort was an unexpected finding
with potential implications for using liquid biopsies as a screening tool. Indeed a survey of the
literature shows that KRAS mutations in apparently healthy samples have been previously
described (See Supplemental table 1) both in a liquid biopsy setting, and in autopsy series (in
non-cancerous pancreata). It is important to mention that in an era where highly sensitive
detection techniques are now available, detection rates for “background” oncogenic mutations
are likely to increase. It is possible that the finding of such mutations describe a pre-malignant
process within the pancreas or a KRAS-mediated malignancy outside the pancreas. Perhaps,
these mutations accumulate in organs with increasing age but the rate at which these mutations
progress to invasive cancer is unknown. Mutant KRAS findings in the normal controls of the
discovery cohort suggests that accumulation of driver mutations may be an age-related
phenomena as recently described by Krimmel and colleagues for TP53 mutations in control
patients (143). However, no association of age and mutant KRAS status in healthy controls was
found in our validation cohort. For purposes as an early cancer-screening diagnostic, the
specificity of our approach would need to be improved possibly by requiring a minimum KRAS
mutation allele frequency to make a positive mutant status call, which is the focus of continued
work. Additional biomarkers, such as other cancer DNA mutations or protein biomarkers could
also be added into the screening model to increase the sensitivity to make it clinically useful.

In the setting where the patient’s cancer status is known a priori, then the utility of a liquid biopsy
lies in the ability to observe serially the response of genetic mutations as a form of personalized
biomarkers to therapy. It is necessary to consider that KRAS mutations as a PDAC biomarker
may be of particular value in terms of assessing response to therapy in those 5-20% of patients
who do not express the Sialyl Lewis-A, or CA 19-9 antigen (144), and furthermore in those
patients in whom CA-19-9 becomes unreliable in the frequent setting of obstructive jaundice.
Additionally, the radiologic appearance and response of PDAC to therapy on cross-sectional
55

imaging is negligible to the point that non-progression on therapy has become a qualifier to
proceed to surgery in borderline-resectable patients (145).

Conclusion
In this study, exoDNA outperformed cfDNA for the detection of mutant KRAS in PDAC patients.
Further, the exoDNA detection rate of patients with early stage tumors is greater than that
previously reported. However, a substantial portion of healthy control patients also exhibited
KRAS mutations. This suggests that follow-up studies more generally focused on uncovering
the prevalence of known cancer mutations (in addition to KRAS mutations) in healthy individuals
are needed to try to put these mutations into biological context and to ultimately understand their
clinical repercussions.

In the context of liquid biopsy, the application for ultrasensitive

identification of a single genetic mutation as a predictor for PDAC may be limited.

56

Chapter 4 – Predictive and prognostic utility of liquid biopsies in pancreatic
cancer
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Abstract
Background and Aims: We aim to investigate the clinical utility of liquid biopsies, specifically
circulating tumor DNA (ctDNA) and exosomal DNA (exoDNA) in localized and metastatic
pancreatic cancer.

Methods: We have utilized liquid biopsies to measure KRAS mutant allele frequency (MAF) by
droplet digital PCR (ddPCR) in paired exoDNA and ctDNA in a prospective cohort of 194
localized and metastatic pancreatic cancer patients, comprising 425 blood samples.

Results: Concordance rates of KRAS mutations present in tissue and detected in liquid biopsies
was 95.5% in 34 patients. Among 34 potentially resectable patients, an increase in exoDNA
following neoadjuvant therapy was significantly associated with progressive disease (p=0.003),
while profiling of ctDNA in this cohort did not reveal significant correlations to outcomes.
Metastatic patients (n=104) with detectable ctDNA at baseline status experienced shorter
progression free (PFS) (HR 1.8, 95% CI 1.1 – 3.0, p=0.019), and overall survival (OS) (HR 2.8,
95% CI 1.4-5.7, p=0.0045) on univariate analysis. On multivariate analysis, exoDNA MAF ≥5%
emerged as a significant predictor of shorter PFS (HR 2.28, 95% CI 1.18-4.40, p=0.014) and OS
(HR 3.46, 95% CI 1.40-8.50, p=0.007). A multi-analyte approach revealed detection of both
ctDNA and exoDNA MAF ≥5% at baseline treatment naïve status as a significant predictor of OS
(HR 7.73, 95% CI 2.61-22.91, P=0.00002) on multivariate analysis. Further, on longitudinal
monitoring in 34 metastatic patients, an exoDNA KRAS MAF peak

≥1% was significantly

associated with radiological progression (p=0.0003).

Conclusions: In a large clinical evaluation of pancreatic cancer, we demonstrate how the use
of exoDNA and ctDNA provide complementary strategies for prognostication and therapeutic.
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Introduction
Although rare, pancreatic ductal adenocarcinoma (PDAC) has recently become the third leading
cause of cancer related deaths with projections of it rising to the second leading cause of cancer
deaths within the next decade (1). While surgical resection provides a potential curative option
in PDAC, only a minority of patients (<15%) will be diagnosed with disease that is amenable to
surgery, and even in this subset of patients, 5 year overall survival (OS) rates remain below 30%.
Neoadjuvant therapies are increasingly being adopted to enhance local disease control in
resectable patients. As most PDAC patients present with surgically unresectable tumors, current
therapeutic options in this patient population has resulted in modest benefits in OS with no means
to personalize therapy currently. Among both localized and metastatic patient populations, there
still remains a significant unmet need in developing more effective strategies for therapeutic
stratification and management.

The use of blood based biomarkers for cancer diagnosis and therapeutic stratification has gained
significant traction in cancer in the form of circulating proteins, RNA, and DNA. Specifically,
circulating tumor DNA (ctDNA) detection in the blood of breast, colorectal, and lung cancer
patients, amongst others, has shown clinical relevance in identifying patient relapses (146-150).
In the context of PDAC, the use of ctDNA as a clinically significant biomarker has been
inconsistent in regards to its prognostic and predictive potential (42, 82, 151-153). Additional
sources of DNA and RNA in circulation have been recently identified in the form of microvesicles
known as exosomes (154). Previous studies have shown the utility of profiling the genomic
content of exosomes (exoDNA) as a surrogate for the mutational landscapes of established
cancers, and for early detection (70, 74, 82). These 40-150nm lipid bilayer membrane bound
vesicles are believed to form protective barriers of nucleic acid material from nuclease induced
degradation in the plasma, thus allowing for the native material to exist in a high molecular weight
format compared to ctDNA which is mostly found at 170bp size. Importantly, this could allow for
greater resolution and sensitivity of molecular profiling of high quality DNA material.
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In this study, we aimed to compare the utility of tumor monitoring in localized and metastatic
PDAC patients using paired exoDNA and ctDNA, to determine how they may be used in a
complementary manner for prognostication and therapeutic stratification. We performed
longitudinal collection in a large prospective cohort of PDAC patients with localized and
metastatic cancer, such that the dynamics of KRAS mutation detection in circulation could be
correlated with disease progression and compared with standard readouts, such as imaging and
CA19-9. To our knowledge, this study represents the first comprehensive comparison of these
liquid biopsy compartments in the context of clinical utility. Additionally, we believe the
longitudinal aspects of this study have implications for potential real-time therapeutic stratification
of PDAC patients.
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Study Design
Patients who were clinically and histologically confirmed as localized or metastatic pancreatic
adenocarcinoma, defined by American Joint Committee on Cancer guidelines, were enrolled in
this longitudinal cohort study. Metastatic disease was based on surgical or radiologic
confirmation. A total of 194 patients were recruited at MD Anderson Cancer Center through
informed consent following institutional review board (IRB) approval (PA14-0552 and PA110670) and treated between 04/07/2015 to 10/13/2017 (Figure 6). Of these, 104 patients
presented at baseline treatment naïve status with metastatic PDAC. If receiving first-line therapy,
treatment naïve patients underwent pre-treatment CT imaging and followed every 2-3 months
with restaging imaging after initiation of chemotherapy. Progression in all patients was
determined based on routine clinical evaluation by a blinded board certified radiologist based on
RECIST 1.1 criteria of CT imaging. Progression free survival was defined by the time from start
of first line therapy to progression based on CT restaging imaging.

61

Figure 6: Patient population cohorts for baseline prognostication and longitudinal follow-up

Results

Characteristics of patients undergoing liquid biopsies
Study overview and patient stratification are presented in, Table 4. A total of 318 blood samples
from 123 metastatic and 107 blood samples from 71 localized resectable patients were profiled
using ddPCR. Median follow-up time for all patients was 187 days. ExoDNA and ctDNA profiled
at baseline treatment naïve status revealed KRAS mutation detection rates of 61% and 53%,
respectively in metastatic patients and 38% and 34%, respectively in localized disease patients
(Figure 7A, B). To determine prevalence of circulating mutational events in other pancreatic
diseases, an additional 37 patients with pancreatic lesions were evaluated for KRAS mutations
in exoDNA and ctDNA. Mutation detection rates were 12% (3/25) and 16% (4/25) for pancreatic
cysts, 25% (3/12) and 17% (2/12) for non-neoplastic pancreatic disease, within exoDNA and
ctDNA respectively.
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Table 4: Patient characteristics and stratification
Characteristics
Average
Median
Range
Male
Female
Hispanic or Latino
Not Hispanic or Latino
Asian
Black or African-American
Caucasian (White)
Native and Other
Head of Pancreas
Tail of Pancreas
Body of Pancreas
Neck of Pancreas
Liver
Lung
Peritoneal
Ovarian
Death PC
Death other
Alive
Lost to Follow-up
Lifelong Non-smoker
Current reformed smoker
Current smoker
Not Available, EMR
No
Yes
Denied
Not Available-EMR
No
Long-standing type 2 diabetes
Newly-diagnosed diabetes-within 1
Long-standing type 1 diabetes
Not Available, EMR
No
Not Available-EMR
Yes
Family history of cancer
Familial PC
Progressed
No Progression

exoDNA
KRAS ≥ 5
KRAS < 5
Age (years)
64.4
63.2
65
65
60
65
(39-86)
(45-86)
(39-84)
Sex/Gender
60 (57.7)
23 (22.1)
37 (35.6)
44 (42.3)
10 (9.6)
34 (32.7)
Ethnicity
9 (8.7)
3 (2.9)
6 (5.8)
95 (91.3)
30 (28.8)
65 (62.5)
Race
3 (2.9)
1 (1)
2 (1.9)
11 (10.6)
4 (3.8)
7 (6.7)
85 (81.7)
26 (25)
59 (56.7)
5 (4.8)
2 (1.9)
3 (2.9)
Tumor Location
47 (45.2)
12 (11.5)
35 (33.7)
25 (24)
10 (9.6)
15 (14.4)
30 (28.8)
11 (10.6)
19 (18.3)
2 (1.9)
1 (1)
1 (1)
Tumor Metastasis
82 (78.8)
31 (29.8)
51 (49)
11 (10.6)
0 (0)
11 (10.6)
10 (9.6)
2 (1.9)
8 (7.7)
1 (1)
0 (0)
1 (1)
Outcome
32 (30.8)
16 (15.4)
16 (15.4)
2 (1.9)
18 (17.3)
18 (17.3)
58 (55.8)
11 (10.6)
47 (45.2)
11 (10.6)
4 (3.8)
7 (6.7)
Smoking History
53 (51)
14 (13.5)
39 (37.5)
29 (27.9)
10 (9.6)
19 (18.3)
6 (5.8)
2 (1.9)
4 (3.8)
16 (15.4)
7 (6.7)
9 (8.7)
Alcohol History
46 (44.2)
14 (13.5)
32 (30.8)
43 (41.3)
14 (13.5)
29 (27.9)
8 (7.7)
4 (3.8)
4 (3.8)
7 (6.7)
1 (1)
6 (5.8)
Diabetes History
64 (61.5)
21 (20.2)
43 (41.3)
25 (24.0)
7 (6.7)
18 (17.3)
7 (6.7)
4 (3.8)
3 (2.9)
1 (1)
0 (0)
1 (1)
7 (6.7)
1 (1)
6 (5.8)
Chronic Pancreatitis History
92 (88.5)
29 (27.9)
63 (60.6)
9 (8.7)
4 (3.8)
5 (4.8)
3 (2.9)
0 (0)
3 (2.9)
Family history of Cancer
71 (68.3)
21 (20.2)
50 (48.1)
6 (5.8)
2 (1.9)
4 (3.8)
Progression
66 (63.5)
53 (51)
13 (12.5)
38 (36.5)
23 (22.1)
15 (14.4)
Total Patients

ctDNA
KRAS > 0

Fisher Test
KRAS = 0

63.1
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exoDNA

ctDNA

67.1
67

(39-86)

(46-84)

41 (39.4)
29 (27.9)

19 (18.3)
15 (14.4)

7 (6.7)
63 (60.6)

2 (1.9)
32 (30.8)

2 (1.9)
9 (8.7)
56 (53.8)
3 (2.9)

1 (1)
2 (1.9)
29 (27.9)
2 (1.9)

31 (29.8)
18 (17.3)
20 (19.2)
0 (0)

16 (15.4)
7 (6.7)
10 (9.6)
2 (1.9)

60 (57.7)
6 (5.8)
4 (3.8)
0 (0)

22 (21.2)
5 (4.8)
6 (5.8)
1 (1)

24 (23.1)
10 (9.6)
36 (34.6)
7 (6.7)

8 (7.7)
26 (25)
22 (21.2)
4 (3.8)

33 (31.7)
20 (19.2)
4 (3.8)
13 (12.5)

20 (19.2)
9 (8.7)
2 (1.9)
3 (2.9)

32 (30.8)
28 (26.9)
7 (6.7)
3 (2.9)

14 (13.5)
15 (14.4)
1 (1)
4 (3.8)

44 (42.3)
14 (13.5)
6 (5.8)
1 (1)
5 (4.8)

20 (19.2)
11 (10.6)
1 (1)
0 (0)
2 (1.9)

59 (56.7)
8 (7.7)
3 (2.9)

33 (31.7)
1 (1)
0 (0)

45 (43.3)
4 (3.8)

26 (25)
2 (1.9)

47 (45.2)
23 (22.1)

19 (18.3)
15 (14.4)

P-value
CI
Odds Ratio
P-value
CI
Odds Ratio
P-value

0.135
0.817
2.1
1
0.164
1.092
0.8814

P-value

0.4439

0.2999

P-value

0.02515

0.04322

P-value

0.00312

0.0004775

P-value

0.5543

0.5641

P-value

0.5591

5.7

5.49

0.8345
0.447
1.11
0.7144
0.312
1.769
0.795

18.422

0.3651

P-value

0.4924

0.4331

P-value

0.5506

0.5492

0.03888
0.993
2.632

0.2846
0.635
1.606

P-value
CI
Odds Ratio

2.758

4.048

When comparing all patient populations, those with metastatic disease had significantly greater
circulating mutant allelic fraction (MAF) of KRAS compared to localized disease and panceatic
cyst patients (Figure 7C).

Patients with localized disease had significantly greater MAF

compared to panceatic cyst patients. We also determined gold standard validation of
concordance rates between exoDNA and ctDNA with tumor tissue for KRAS mutation detection
using ddPCR (Table 5). Concordance among 22 surgically resected primary pancreatic tumors
was 95.5% and 68.2% for exoDNA and ctDNA respectively, while concordance from 12 samples
derived by fine needle aspirates was 83.3% and 66.8% for exoDNA and ctDNA respectively.
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Figure 7 Mutant KRAS detection characteristics in a prospective cohort of tumor and benign
pancreatic disease
Venn diagram of detection rates of codon 12/13 mutant KRAS by ddPCR among (A) 102
metastatic and (B) 66 localized PDAC patients with matched exoDNA and ctDNA analysis. (C)
MAF of KRAS mutations detected through ddPCR in exoDNA and ctDNA among baseline
treatment naïve localized and metastatic patients, and patients with benign pancreatic cysts and
non-neoplastic pancreatic disease. Greater median MAF in exoDNA compared ctDNA in
metastatic patients trended towards significance (p = 0.05), paired analysis performed by
Wilcoxon test. Those patients with metastatic disease had higher KRAS MAF in both exoDNA
(p<0.0001) and ctDNA (p=0.0004) when compared to patients with localized disease, by MannWhitney test. (p<0.05*, p<0.01**, p <0.001***, p<0.0001****)
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Table 5 Concordance rates of tumor tissue and liquid biopsy mutant KRAS detection
Surgical Tissue Samples Total Samples
Liquid Biopsy match Tissue
exoDNA match Tissue
cfDNA match Tissue
Sample
exoDNA
MK238
MK240
MK248
+
MK257
+
MK259
+
MK272
+
AM62
+
AM88
MK44
+
MK99
MK116
MK127
MK160
MK191
+
MK212
MK217
+
MK230
+
MK152
MK227
+
AM95
MK307
DH14
+
ExoDNA
Sensitivity
Specificity
PPV
NPV
FNA Samples

Sample
WB02
MK151
MK229
MK10
MK17
MK27
GV79
BW13
WB27
AM74
MK12
MK42
ExoDNA
Sensitivity
Specificity
PPV
NPV

22
20
21
14
cfDNA
+
+
+
+
+

95.45
95.45
68.18
Tissue KRAS
+
+
+
+
+
+
+
+
+
+
+
+
ctDNA
Sensitivity
Specificity
PPV
NPV

91.67%
100%
100
90.91 (CI 60.49 - 98.49)
Total Samples
Liquid Biopsy match Tissue
exoDNA match Tissue
cfDNA match Tissue
exoDNA
+
+
+
+
+
+
+
+
+
+

90.00%
50%
90 (CI 68.91 - 97.34)
50 (CI 8.96 - 91.04)

Concordance (%)

12
11
10
8
cfDNA
+
+
+
+
+
+
+
+

50%
100%
100
62.50 (48.63 - 74.59)
Concordance (%)
91.67
83.33
66.67

Tissue KRAS
+
+
+
+
+
+
+
+
+
+
ctDNA
Sensitivity
Specificity
PPV
NPV

50%
90%
85.71 (CI 46.21 - 97.67)
60.00 (45.09 - 73.26)
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Serial liquid biopsies in localized PDAC patients receiving neoadjuvant therapy are
predictive of eventual surgical resection
A total of 34 PDAC patients with localized disease were serially monitored during neoadjuvant
therapy, comprising 68 cumulative blood draws taken at baseline and after the completion of
neoadjuvant therapy (Table 6).

Kinetics of circulating KRAS mutational burden were then

measured in exoDNA and ctDNA using ddPCR. Mutant KRAS was detected in 41% (14/34) and
32% (11/34) of patients in exoDNA and ctDNA, respectively at baseline. Among the patients
monitored, 50% (17/34) underwent subsequent surgical resection given an absence of
Table 6: Clinical characteristics of patients receiving neoadjuvant chemotherapy

Characteristics

Total
(N=34)

Progression
(n=17)

Nonprogression
(n=17)

χ²/t

p

Age (year)

M±SD
64.9±9.1

M±SD
65.8±11.1

M±SD
64.4±8.3

0.332

0.743

Primary tumor size

30.2±9.1

30.5±11.6

30.0±8.0

0.122

0.904

N (%)

N (%)

N (%)

Male
Female
Tumor location
Head
Body or Tail
Neoadjuvant
Chemotherapy
GEM + ABR
FOLFIRINOX
Neoadjuvant XRT
30Gy
50.4Gy
N/A
Radiosensitizing
Agent
Capecitabine
Gemcitabine
N/A
Change of ExoDNA
KRAS
No decrease
Decrease
Change of cfDNA
KRAS
No decrease
Decrease
Change of CA 19-9
Increase

20
14

11
6

9
8

0.73 a

27
7

13
4

14
3

1.000 a

18
16

10
7

8
9

0.49 a

11
15
8

5
6
6

6
9
2

1.000 a

22
4
8

10
1
6

12
3
2

0.61 a

21
13

16
1

5
12

0.0002 a

25
9

11
6

14
3

0.44 a

9

8

1

0.003 a

Non-increase

18

4

14

Gender

disease progression, compared to 50% who experienced disease progression, primarily
manifesting as the emergence of new metastatic lesions. In this cohort, reduction in exoKRAS
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MAF from baseline at the completion of neoadjuvant therapy was significantly correlated with
surgical resection, while the reverse was true for patients who did not emerge as surgical
candidates (OR 38.4, CI 3.95-373.3, p=0.0002) (Figure 8A, B). Specifically, among patients who
underwent resection, 71% (12/17) experienced a decrease in exoKRAS MAF from baseline
treatment naïve values, while in those patients who did not, 16/17 (94%) saw an increase or no
change in KRAS MAF in exoDNA from baseline status. As one example, in an index case, a rise
in KRAS MAF in exoDNA suggested progressive disease, though that was initially not detectable
by CA19-9 or CT imaging. On laparotomy, CT-occult omental metastasis was found resulting in
an aborted resection. This correlation between changes in KRAS MAF and resectability was,
however, not seen with ctDNA. After eliminating those patients who were considered as nonexpressors of CA19-9 (values below 37 U/ml), changes in CA19-9 were also significantly
correlated to those patients likely to undergo surgery (OR 28.0, CI 2.65-295.9, p=0.003). Among
three patients where no detectable exoKRAS mutant was found, CA19-9 was able to predict
progressive disease, underlining the complementary nature of how these biomarkers can be
utilized.
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Figure 8 Liquid biopsy tumor monitoring of patients receiving neoadjuvant therapy
(A) Tumor monitoring before and after neoadjuvant chemoradiation in a patient
experiencing progression undetectable by CA19-9 (blue line) or radiological based
RECIST 1.1 (black line). (B) MAF kinetics of exoDNA and ctDNA before and after
neoadjuvant therapy shows a significant correlation between a rise or no change in
exoDNA MAF and progression (OR 38.4, CI 3.95-373.3, p=0.0002). No significant
correlation was detectable by ctDNA. Changes in CA19-9 from baseline were also
significantly associated to progressive disease (OR 28.0, CI 2.65-295.9, p=0.003).
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Clinical correlates of liquid biopsies at presentation in metastatic PDAC patients
Among metastatic PDAC patients, clinical characteristics at the time of presentation were
grouped according to exoDNA and ctDNA status are shown in Table 4. There was no significant
association between KRAS MAF in exoDNA and ctDNA, and presenting characteristics. Overall,
66 (63%) had experienced radiologic progression and 69 (67%) were still alive at mila last followup date.

Patients who experienced progression during serial monitoring or succumbed to

disease had higher KRAS MAF in exoDNA at presentation (Wilcoxon signed-rank tests, p=0.03
and p=0.01, respectively) when compared to those that had not progressed (Figure 9). CtDNA
tumor burden, as measured by KRAS MAF at presentation, was also significantly associated with
survival (p=0.03) (Figure 9B). Patients with liver metastatic lesions had a significantly greater
KRAS MAF in exoDNA and ctDNA, compared to patients with isolated lung and peritoneal lesions
(p=0.04) (Figure 10A-B). This correlation was likely impacted by the fact that patients with
metastasis to the liver have larger volume of lesions compared to those with isolated lung and
peritoneal metastases (Figure 10C). In fact, on linear regression analysis, exoDNA and ctDNA
KRAS MAF at presentation was significantly correlated with tumor size as measured by total sum
of lesion diameters (p=0.035 and p=0.0008, respectively) (Figure 11). Additionally, patients with
progressively worse ECOG performance status harbored significantly greater KRAS MAF
(Figure 12) .
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Figure 9 Correlates of survival and KRAS MAF at baseline treatment naïve
status.
A. Median MAF of exoKRAS in metastatic patients is significantly greater in those
patients that have progressed (p = 0.03) and are deceased compared (p=0.01) to
those that are not. B. Median MAF of ctKRAS is significantly greater in those
patients that are deceased compared (p=0.03) to those that are not, by MannWhitney test. All axis have been scaled to log10 for visual representation.
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Figure 10 Distribution of exoKRAS, ctKRAS, and SLD stratified against type of metastasis
Boxplots of the distributions. Log10( x + 1) was used to transform the KRAS results. X + 1 was used to
keep KRAS MAF values at 0. The Wilcoxon test was used to compare between two subsets and the
Kruskal-Wallis was used to compare between all three. A. exoKRAS MAF (N = 103) plotted against
metastasis type. Median and range for Liver, Lung and Peritoneal Metastasis were 1.463 (0-59.091), 0
(0-1.763), 0 (0-25.358) respectively. P-value between pairs of Liver and Lung, Liver and Peritoneal, and
Lung and Peritoneal were 0.028, 0.15, 0.72 respectively. P-value for all three was 0.044. B. exoKRAS
MAF (N = 100) plotted against metastasis type. Median and range for Liver, Lung and Peritoneal
Metastasis were 0.760 (0-60.969), 0 (0-0.327, 0 (0-21.664) respectively. P-value between pairs of Liver
and Lung, Liver and Peritoneal, and Lung and Peritoneal were 0.0021, 0.017, 0.58 respectively. Pvalue for all three was 0.00084. C. SLD (Sum of Longest Diameters) (N = 102) plotted against
metastasis type. Median and range for Liver, Lung and Peritoneal Metastasis were 77.5 (21-200), 61
(43-111, 61 (40-181) respectively. P-value between pairs of Liver and Lung, Liver and Peritoneal, and
Lung and Peritoneal were 0.17, 0.56, 0.84 respectively. P-value for all three was 0.36.
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Figure 11 Trend between KRAS MAD and SLD
Linear regressions on between both exoKRAS and ctKRAS and SLD. (A) ExoKRAS
modeled by f(x) = 1.336 + 0.07376x. P-value = 0.0353. R2 = 0.04353, (B) ctKRAS modeled
by f(x) = -3.154 + 0.1145x. P-value = 0.000848. R2 = 0.1089
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Figure 12 Distribtion of exoKRAS and cfKRAS stratified for ECOG performance
status.
Boxplots of the distributions. Log10( x + 1) was used to transform the KRAS results. X +
1 was used to keep KRAS MAF values at 0. The Wilcoxon test was used to compare
between two subsets and the Kruskal-Wallis was used to compare between all
categories.
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Prognostic impact of liquid biopsy parameters at presentation in metastatic PDAC
patients
To avoid confounding effects of chemotherapy on exoDNA and ctDNA kinetics, we performed
subset analysis on 104 metastatic patients who were treatment naïve at the time of presentation.
An optimal threshold for ctDNA was assessed by receiver operating curve (ROC) analysis with
the optimal cutoff achieving a sensitivity and specificity of 60% and 54% for OS, and 53% and
50% PFS, respectively. As previously described in other tumor types, the presence and absence
of detectable ctDNA (i.e., any mutant KRAS on ddPCR) was significantly associated with patient
outcomes (146, 149). For example, any detectable ctDNA was associated with significantly
shorter PFS (log-rank test; HR 1.93, 95% CI 1.15-3.22, p=0.012) with a median PFS of 118
versus 321 days (for detection versus no detection, respectively, (Figure 13B). Detectable
ctDNA also showed shorter OS (HR 2.36, 95% CI 1.16-4.79, p=0.018) with a median OS of 258
vs 440 days (detection and no detection, respectively, (Figure 13B). In the context of exoDNA,
an optimal exoKRAS MAF was determined to be 5%, achieving the optimal cutoff by ROC
analysis with a sensitivity and specificity of 51% and 85% for OS, and 89% and 36% for PFS
respectively. Using this threshold of 5% KRAS MAF, patients with higher than 5% KRAS MAF
were significantly associated with reduced PFS (HR 4.78, 95% CI 2.47-9.26, p<0.0001) and OS
(HR 7.31, 95% CI 3.15-17.00, p<0.0001) on Kaplan-Meier analysis (Figure 13A). Similarly,
survival analyses of the standard clinical biomarker CA19-9 (Figure 14) demonstrated that
patients with a CA19-9 ≥ 300 at treatment naive presentation had worse OS (p=0.023), with
PFS trending towards significance (p=0.06).
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Using a Cox regression model (Table 7), univariate analysis revealed KRAS MAF ≥5% in
exoDNA (HR 3.5, 95% CI 2.1 – 5.9, p<0.0001) and any ctDNA detection (HR 1.8, 95% CI 1.1 –
3.0, p=0.019), were significantly associated with shorter PFS. On multivariate analysis, exoKRAS
≥5% remained the only significant predictor of PFS (HR 2.28, 95% CI 1.18-4.40, P=0.014).
Combining KRAS MAF ≥5% in exoDNA or ctDNA detection with a CA19-9 ≥300 did not reveal
an increase in predictive significance of these biomarkers for poorer PFS.

Figure 13 Kaplan-Meier curve stratification of baseline treatment naïve metastatic
patients.
(A) Patients with exoKRAS ≥5% experienced worse PFS (median 71 vs 200 days) and OS
(median 204 vs 440 days). Detection of ctDNA was significantly associated with worse PFS
(median 118 vs 231 days) and OS (258 days vs 440 days).
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Figure 14 Kaplan Meier curve stratification of baseline treatment naïve patients
based on CA19-9.
(Top) Patients with CA19-9 ≥300 experienced worse OS (median 204 vs 264 days, p
= 0.023), (Bottom) but not significantly worse PFS (p=0.06).
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Table 7 Univariate and multivariate analysis of clinical characteristics with exoKRAS and cfKRAS

Univariate Cox Regression (PFS)
beta
exoKRAS >5%
ctDNA Detection
Age
Gender (Male v Female)
ECOG (0 v 1)
ECOG (0 v 2)
ECOG (0 v 3)
Regimen: GEM v FOLFIRINOX
Metastatic site: Liver v Lung
Metastatic site: Liver v Peritoneal
CA19-9 > 300

1.2
0.59
-0.0027
0.45
0.6766
0.502
0.442
0.53
-0.775
-0.719
0.41

Multi-Analyte Analysis
exoKRAS >5% and CA19-9 > 300
exoKRAS >5% or CA19-9 > 300
ctDNA Detection and CA19-9 > 300
ctDNA Detection or CA19-9 > 300
exoKRAS >5% + ctDNA Detection + CA19-9 > 300

1.2
0.64
0.75
0.52
1.4

HR (95% CI for HR)
3.5 (2.1-5.9)
1.8 (1.1-3)
1 (0.97-1)
1.6 (0.94-2.6)
1.5 (0.72-3.04)
2.0(0.79-5.03)
1.51(0.40-5.68)
1.7 (0.99-2.9)
0.4605 (0.2040-1.039)
0.4873 (0.2043-1.162)
1.5 (0.89-2.6)

3.2 (1.9-5.5)
1.9 (1.1-3.3)
2.1 (1.3-3.5)
1.7 (0.89-3.2)
3.9 (2.2-7.1)

wald.test p.value
22
3.5E-06
5.5
0.019
0.04
0.83
3
0.084
2.79
0.289
2.79
0.145
2.79
0.541
3.7
0.054
5.29
0.0619
5.29
0.1051
2.4
0.12

18
4.7
8
2.6
21

2.00E-05
0.03
0.0048
0.11
5.20E-06

Multivariate Cox Regresssion Analysis (PFS)
exoKRAS >5%
ctDNA Detection
Gender (Male v Female)
ECOG (0 v 1)
ECOG (0 v 2)
ECOG (0 v 3)
Metastatic site: Liver v Lung
Metastatic site: Liver v Peritoneal
CA19-9 > 300
Regimen: GEM v FOLFIRINOX

exp(coef) exp(-coef)
2.2808
1.3236
1.3433
1.2631
2.8138
1.1913
0.5615
0.5103
1.07
0.577298

0.4384
0.7555
0.7444
0.7917
0.3554
0.8394
1.7809
1.9594
0.9346
1.78122

lower .95 upper .95 Pr(>|z|)
1.1827
4.398 0.0139 *
0.7568
2.315
0.3257
0.7396
2.44
0.3324
0.5785
2.758
0.5577
0.9723
8.143 0.0564 .
0.2942
4.825
0.8062
0.2193
1.438
0.2289
0.2083
1.25
0.1413
0.6041
1.895
0.8166
0.9987
3.177
0.0505

Likelihood ratio test= 26.36 on 9 df, p=0.001782
Wald test
= 26.03 on 9 df, p=0.00202
Score (logrank) test = 29.31 on 9 df, p=0.0005753
Univariate Cox Regression (OS)
beta
exoKRAS >5%
ctDNA Detection
Age
Gender (Male v Female)
ECOG (0 v 1)
ECOG (0 v 2)
ECOG (0 v 3)
Regimen: GEM v FOLFIRINOX
Metastatic site: Liver v Lung
Metastatic site: Liver v Peritoneal
CA19-9 > 300
Multi-Analyte Analysis
exoKRAS >5% and CA19-9 > 300
exoKRAS >5% or CA19-9 > 300
ctDNA Detection and CA19-9 > 300
ctDNA Detection or CA19-9 > 300
exoKRAS >5% + ctDNA Detection + CA19-9 > 300

1.5
1
0.017
0.33
0.2677
1.2708
0.8247
0.85
-1.2193
-0.2011
1.2

HR (95% CI for HR)
wald.test p.value
4.6 (2.2-9.7)
17 0.000041
2.8 (1.4-5.7)
8
0.0045
1 (0.98-1.1)
0.84
0.36
1.4 (0.7-2.8)
0.91
0.34
1.307(0.45-3.81)
6.35
0.624
3.564(1.04-12.3)
6.35
0.0439
2.281(0.41-12.8)
6.35
0.3477
2.3 (1.1-5.2)
4.4
0.036
0.2954 (0.06948-1.256)
2.76
0.0987
0.8178 (0.28198-2.372)
2.76
0.7113
3.2 (1.3-7.7)
6.5
0.011

1.7 5.4 (2.6-11)
1.2 3.3 (1.3-8.6)
1.2 3.4 (1.7-6.7)
1.8 5.8 (1.4-25)
1.9 6.6 (3.1-14)

21
6
12
5.8
24

4.90E-06
0.015
0.00052
0.016
9.30E-07

Multivariate Cox Regresssion Analysis (OS)
exoKRAS >5%
ctDNA Detection
ECOG (0 v 1)
ECOG (0 v 2)
ECOG (0 v 3)
Metastatic site: Liver v Lung
Metastatic site: Liver v Peritoneal
CA19-9 > 300
Regimen: GEM v FOLFIRINOX

exp(coef) e xp(-coef)
3.4553
1.6662
1.2134
3.1891
1.703
0.5372
1.4894
2.1451
0.612157

0.2894
0.6002
0.8242
0.3136
0.5872
1.8614
0.6714
0.4662
1.844406

lower .95 upper .95
1.4044
8.501 0.00695 **
0.7416
3.744
0.21638
0.3945
3.732
0.73586
0.8828
11.52 0.07676 .
0.2692
10.772
0.57162
0.1102
2.62
0.44215
0.4822
4.6
0.48868
0.8415
5.468
0.10994
0.7615
4.468
0.175

Likelihood ratio test= 29.01 on 8 df, p=0.0003163
Wald test
= 25.22 on 8 df, p=0.001426
Score (logrank) test = 30.93 on 8 df, p=0.0001446
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For OS, KRAS MAF ≥5% in exoDNA (HR 4.6, 95% CI 2.2-9.7, p<0.0001), any ctDNA detection
(HR 2.8, 95% CI 1.4-5.7, p=0.0045), CA19-9 ≥300 (HR 3.2, 95% CI 1.3-7.7, p=0.011), and an
ECOG performance status score of 2 (HR 3.56, 95% CI 1.04-12.3, p=0.044) were significant
predictors of poorer outcomes on univariate analysis. On multivariate analysis, exoKRAS ≥5%
(HR 3.46, 95% CI 1.40-8.50, P=0.007) remained as a significant predictor of poorer OS. An
exoKRAS MAF ≥5% together with a CA19-9 ≥300 (HR 6.41, 95% CI 2.31-17.80, P=0.0004) at
baseline treatment naïve status resulted as a significant predictor of poorer OS. Although on its
own, ctDNA did not emerge as a significant predictor on multivariate analysis, detection of ctDNA
emerged as a significant predictor of poorer OS when occurring with a CA19-9 ≥300 at baseline
treatment naïve status (HR 6.37, 95% CI 2.36-17.24, P=0.0003). Additionally exoKRAS MAF
≥5% and ctDNA detection was correlated to poorer OS

(HR 7.73, 95% CI 2.61-22.91,

P=0.00002) on multivariate analysis when both occurring at baseline treatment naïve status in
the same patient, underlining the potential complementary nature of these biomarkers).

Longitudinal monitoring of metastatic PDAC using serial liquid biopsies anticipates ontreatment progression
To fully evaluate the utility of liquid biopsies in monitoring the natural history of metastatic PDAC,
we profiled exoDNA and ctDNA through 123 serial blood draws among 34 patients with a median
follow-up time of 202 days. Specifically, we selected patients who had at least 2 blood draws
taken during a concurrent therapeutic regimen, with two or more restaging imagings taken at
standard 2-3 month intervals.

Among the monitored patients, 20/34 (59%) progressed on

therapy, with a median time to progression of 176 days. Patients who did not progress had a
median follow-up time of 300 days. Analysis of plasma samples revealed that a KRAS MAF
peak of ≥1% in any on-treatment serial exoDNA sample was significantly associated with
eventual disease progression, as determined by RECIST 1.1 (p < 0.0001) (Figure 15). The
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optimal MAF of ctDNA KRAS and exoDNA KRAS in predicting progression was assessed by
ROC analysis with only exoKRAS achieving predictive significance with a sensitivity and
specificity of 79% and 100%, respectively. Among the 20 patients who progressed, 16 (80%)
saw an exoDNA KRAS MAF peak of

≥1% compared to none in those patients without

progression 14/14 (100%). In contrast, serial ctDNA MAF did not correlate significantly with
presence or absence of progression. Using a threshold of 20% or greater increase of CA19-9
during therapy, the sensitivity and specificity of CA19-9 in predicting progression was 70% and
89%, respectively. Importantly, when assessing for the length of time when KRAS MAF in serial
exoDNA exceeded ≥1% and the subsequent onset of radiological progression, exoKRAS had a
significantly longer lead time (median of 50 days, p=0.03) compared to lead times obtained by
using 20% or greater increase in serial CA19-9 (which essentially coincided with the onset of
radiological progression) (Figure 15C). Additional application of Bayesian inference provided us
with posterior probabilities of 100% chance of progression given an exoKRAS peak ≥1%
(P(Progression | exoKRAS ≥1%)) and 90% chance of prolonged response to therapy (No
progression recorded before censor) given that exoKRAS remains <1% (P(No Progression |
exoKRAS <1%)).
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Figure 15 Tumor monitoring of metastatic PDAC using liquid biopsies
(A) Tumor monitoring using serial liquid biopsies demonstrating correlation between a exoKRAS
peak ≥1% (red line) and radiological progression based on RECIST 1.1 (black line). The standard
pancreatic cancer biomarker is plotted (blue) as well as ctKRAS (green) for comparison. (B)
Tumor monitoring among 34 patients demonstrates the ability of exoKRAS peaks ≥1% (red circle)
to predict radiological progression (green bar). Peaks are identified in 11/14 patients that
progressed compared to in no patients that did not progress, 9/9. exoKRAS peak is significantly
associated to progression (p =0.0003) on Fisher’s exact test with an Odds ratio of 62.4 (95% CI
2.852 - 1367). (C) MAF KRAS peak demonstrates a significantly greater median lead time in
predicting progression of 50 days (p=0.03) from the time clinically detectable progression was
evident on CT imaging compared to CA19-9 (median lead time = 0 days).
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Discussion
Nucleic acids derived from exosomes have been reported as a novel compartment of high quality
DNA material which is protected from degradation in circulation (70-72). As opposed to ctDNA,
which exists in the 150-170bp range, protected exoDNA is found in a high molecular weight
format that readily lends itself to next generation sequencing (NGS) for molecular profiling. In
our study, we profile matched exoDNA and ctDNA for mutant KRAS alleles by quantitative
ddPCR in a large series of prospectively collected plasma samples from PDAC patients (N=194),
and identify baseline detection rates of 61% and 53% in metastatic disease, and 38% and 34%
in localized disease, for exoDNA and ctDNA, respectively. A substantial minority of patients
(between 12-25%) with pre-neoplastic pancreatic cysts or non-neoplastic pancreatic diseases
(such as chronic pancreatitis) harbored detectable circulating mutant. KRAS mutations are
present in up to 80% of pre-neoplastic pancreatic cysts (including low-grade mucinous cysts)
(155, 156), and thus their detection on ddPCR in the circulation is not surprising. Mutations in
KRAS are also detectable in the pancreas as a consequence of non-neoplastic inflammatory
processes such as chronic pancreatitis, although tissue based studies have confirmed a lower
frequency of mutations than in either cancer or in pre-neoplastic cysts (131, 157, 158). In line
with these observations, and as an indirect derivation of “tissue mutation load”, quantitative
ddPCR found average KRAS MAF to be highest in baseline metastatic samples, followed by
localized disease, cystic lesions and finally, non-neoplastic panceatic diseases, in that order.

Beyond detection of tumor-derived DNA per se in liquid biopsies as a biomarker of an underlying
neoplasm, recent studies have also focused on the potential prognostic value imparted by ctDNA
or exoDNA measurement in cancer patients at the time of presentation. For example, Mohrmann
et al reported that among 41 patients with advanced solid cancers, driver mutation detection by
ddPCR in either exoDNA or ctDNA was associated with overall survival on Kaplan-Meier
analysis, although only exoDNA at the time of presentation was an independent prognostic factor
for OS on multivariate analysis (HR 0.15, 0.03-0.80, p= 0.026) (159). On these lines, several
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studies have evaluated the prognostic potential of liquid biopsies in PDAC, most focusing on
ctDNA measured using digital PCR. In a relatively small study, Earl et al, report KRAS mutant
ctDNA detection in 8/31 (26%) patients across various PDAC stages, with detection being
significantly correlated to OS (HR12.2, p =0.0002) (160). In a larger study of 105 patients,
Hadano et al. report a cumulative rate of 31% ctDNA detection across stages, with median
survival of 13.6 months vs 27.6 months in those patients with detectable versus no detectable
ctDNA, respectively, and a significant association with OS (p<0.0001) (161). In our own series,
detection of ctDNA and exoDNA at presentation were both associated with significant deleterious
impact on OS and PFS on univariate analysis, although only an exoDNA KRAS MAF ≥ 5% was
an independent negative predictor of poor survival on multivariate analysis (HR 2.28, 95% CI
1.18-4.40, p=0.014 for PFS and HR 3.46, 95% CI 1.40-8.50, p=0.007 for OS, respectively) when
used independently. As previous work had demonstrated the utility of using a combination of
biomarkers for early detection, particularly ctDNA and CA19-9 in the context of surgically
resectable pancreatic cancer, we aimed to determine the prognostic significance of combining
ctDNA detection or exoDNA MAF with CA19-9 (162, 163). Although ctDNA detection alone was
not a significant predictor of outcomes, we did observe a combination of ctDNA detection and a
CA19-9 ≥300 at baseline treatment naïve status to be a significant predictor of poorer OS (HR
6.37, 95% CI 2.36-17.24, P=0.0003), demonstrating the utility of a multi-analyte approach. We
also saw this same phenomenon when combining ctDNA detection and exoKRAS MAF ≥5% as
a significant predictor of OS (HR 7.73, 95% CI 2.61-22.91, P=0.00002). Ultimately, these blood
based biomarkers demonstrate complementary utility in prognostic value where the presence of
these thresholds suggests that those patients may require more intense followup to capture
earlier progression, or more aggressive therapy than standard of care to influence outcomes.
This helps underline how each may represent distinct biologies, despite sharing the moniker of
“liquid biopsy”, whereby ctDNA is released from apoptotic or necrotic cells, while exosomes may
represent material released into circulation from rapidly dividing viable cells.
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One major advantage of liquid biopsies is the ability to conduct longitudinal monitoring of ontreatment patients as a readout of therapeutic efficacy. While this is typically conducted in PDAC
with serial imaging scans or with CA19-9, liquid biopsies might provide adjunctive, and potentially
superior, predictive data on treatment response, with an opportunity for anticipating treatment
intervention. In an earlier study, Tjensvoll et al reported pilot data from a cohort of 14 PDAC
patients, using Peptide–nucleic acid–clamp PCR KRAS mutation detection (164). Monitoring
ctDNA levels during chemotherapy demonstrated a correlation with CA19-9 and radiological
progression among 3 patients. In a separate series, Sausen et al., used digital PCR for ctDNA
detection following tumor resection in localized PDAC (36). Among nine patients with detectable
ctDNA and radiological recurrence, the authors report ctDNA detection an average of 3.1 months
after resection compared to 9.6 months when it becomes clinically detectable on CT imaging.
These data suggest a potential role for using liquid biopsies to facilitate earlier detection of
progression than radiological scans. In our cohort, we examined 34 metastatic patients who had
sufficient longitudinal on-treatment follow-up and serial liquid biopsies to report tumor monitoring
outcomes. Although we did not find significant association between progression outcomes with
changes in ctDNA, we did find a significant correlation between exoDNA KRAS MAF and
eventual radiological progression. Specifically, those patients with an exoDNA KRAS MAF ≥1%
on any on-treatment serial biopsy have a 100% probability of progressing, with a median lead
time to radiological progression of 50 days from the first sample with exoDNA KRAS MAF ≥ 1%.
In contrast, patients who maintained exoDNA KRAS MAF <1% on serial monitoring had a 90%
probability of not progressing on therapy in the ~1 year median follow up duration of our study.
We believe this mutant exoDNA “spike” ≥1%, albeit transient, represents a growth spurt of the
underlying cancer, likely coinciding with the incipient onset of resistance to ongoing therapy. The
ability of serial liquid biopsies to predict which PDAC patients are most likely to fail first or second
line chemotherapy is of clinical utility, since it provides an earlier opportunity than radiological
imaging for changing course. It is also important to note, that continued exposure of patients to
ineffective first or second line regimens may result in unnecessary toxicities and deterioration of
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performance status, which might make patients no longer candidates for subsequent line
therapies.

In addition to metastatic patients, our prospective series also examined the utility of serial liquid
biopsies in patients with localized PDAC. At MD Anderson, and increasingly at other centers in
the US, patients with localized disease receive preoperative (neoadjuvant) chemo-radiation
therapy.

The main objective of neoadjuvant therapy is to prolong the survival of patients

undergoing surgery and minimize the use of surgery for patients unlikely to benefit from it (165).
However, indicators of the effectiveness of neoadjuvant therapy and subsequent surgical
resection remain a significant unment need. We postulated that liquid biopsy kinetics between
initiation and culmination of neoadjuvant treatment may predict for response to neoadjuvant
therapy and lack of progression, thus enabling surgery. In fact, a decrease in exoDNA KRAS
MAF (but not ctDNA) between the beginning and the end of neoadjuvant therapy was significantly
correlated with eventual surgical resection, when compared to those patients experiencing a rise
in exoDNA KRAS MAF (OR 38.4, CI 3.95-373.3, p=0.0002). Although this same correlation held
true for CA19-9 (OR 28.0, CI 2.65-295.9, p=0.003) which is not significantly different from
exoDNA, it’s worth noting how liquid biopsies may be used as complementary biomarkers in
those patients that are deemed CA19-9 non-expressors or those patients with obstructive
jaundice, where CA19-9 shows no correlation to progressive disease, as in 33% of patients in
our series. Notably, even in one case where CT imaging did not detect overt progression despite
a rise in exoDNA KRAS MAF, laparotomy confirmed the discovery of CT-occult omental
metastasis. This data suggests a role for serial liquid biopsies, and specifically exoDNA, as a
putative predictive biomarker for disease status following neoadjuvant therapy.
It is important to note several weaknesses of the current study. Although the strategy of using
mutant KRAS molecules as a tumor marker may be theoretically optimal in a disease like PDAC
where KRAS mutation rates exceed 90%, the stochastic nature of circulating nucleic acids
released in circulation may underestimate the true circulating tumor burden if detection is limited
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to a single mutation. This may likely be a contributing factor to the poor predictive potential of
ctDNA in the context of metastatic disease as well as those patients undergoing neoadjuvant
therapy. Of note, we do find notable differences in our previously published exoKRAS and ctDNA
detection rates in metastatic (85% and 57.9%, respectively) and localized disease patients (67%
and 45.5%, respectively) obtained from a retrospective bio-banked cohort (11). The differences
in detection rate are largely due to the fact that exoDNA and ctDNA in the previous study
underwent whole genome amplification to increase sensitivity of KRAS detection in the context
of early detection efforts. Although this was a possibility in the current series, we opted against
amplification as this would have distorted the MAFs found through ddPCR and thus effected our
clinical endpoints. It is important to note that the use of a tumor gene panel (e.g. KRAS, TP53,
CDKN2A, and SMAD4) may achieve greater sensitivity for detection and monitoring (146, 150).
Additionally, the fact that our multigene panel does not cover KRAS hotspot mutations in codon
61, may underestimate our true sensitivity as the current panel has theoretical detection rate of
up to 80% of known KRAS mutations in PDAC. Although our detection rates of KRAS mutant
molecules are relatively modest at 32% to 41% in baseline treatment naïve metastatic patients
based on the liquid biopsy compartment, a fact that may limit the amount of patients that may
benefit from such an assay, when looking at general detection in both compartments at once,
detection rates increase to 73.1%, which is near the theoretical limit of our assay. This underlines
the complementary nature of these biomarkers, especially in setting of low volume disease (such
as post-treatment, or monitoring fore recurrence), whereby the absence of mutant detection in
one does not preclude the ability to gain valuable genomic information in the other. Additionally,
although exoDNA mutant KRAS detection levels compared to ctDNA detection levels are not
significantly better in the current cohort, exosomes provide the added ability to perform specific
enrichment of cancer-derived material, allowing for capture of DNA, RNA, and proteins derived
from tumors for mutation, gene expression, and possibly even neoantigen detection (14). The
need of a gold standard validation is also important when pursuing liquid biopsy assays such as
the one described in this study. As such, recent work has attempted to validate concordance
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between mutations found in liquid biopsies and tissue biopsies (166-171). In the context of
PDAC, acquiring tissue biopsies for molecular profiling is particularly difficult in the metastatic
setting where fine needle aspirates are typically reserved for diagnostic purposes. We thus
selected a small cohort of 34 localized disease patients where concordance rates ranged from
66.7% to 95.5% depending on the liquid biopsy and tissue source. Unsurprisingly, surgical tissue
specimens saw greater rates of concordance, particularly in exoDNA which is likely associated
to the greater sensitivity of mutation detection within exosomes. Overall, KRAS mutation
detection rates was high within liquid biopsies as a whole, although it remains to be seen if
profiling of additional mutations can achieve this sensitivity and specificity.

In conclusion, our study in a relatively large cohort of PDAC patients, comprised of both
metastatic and localized disease, reiterates the predictive and prognostic value of liquid biopsies
in this malignancy. We demonstrate that while the baseline CA19-9, exoDNA, and ctDNA cargo
has prognostic effect, longitudinal monitoring of exoDNA provides unique predictive information
on the outcome of neoadjuvant therapy in localized disease, and in anticipating progression in
the metastatic setting. In contrast to the challenges of repetitive tissue biopsies for visceral
cancers, serial liquid biopsies may provide an attractive alternative strategy to map tumor
evolution in real time, providing an unprecedented insight into how the PDAC genome adapts to,
and eventually becomes recalcitrant, to therapy.
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Chapter 5 – Whole genome, exome, and transcriptome profiling of liquid biopsies with
exoDNA

With permission this chapter is based upon “San Lucas, F. A.*, K. Allenson*, V. Bernard*, J.
Castillo, D. U. Kim, K. Ellis, E. A. Ehli, G. E. Davies, J. L. Petersen, D. Li, R. Wolff, M. Katz, G.
Varadhachary, I. Wistuba, A. Maitra, and H. Alvarez. 2015. Minimally invasive genomic and
transcriptomic profiling of visceral cancers by next-generation sequencing of circulating
exosomes. Annals of oncology : official journal of the European Society for Medical Oncology /
ESMO (*First authorship shared)”
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Abstract
Background: The ability to perform comprehensive profiling of cancers at high-resolution is
essential for precision medicine. Liquid biopsies using shed exosomes provide high-quality
nucleic acids to obtain molecular characterization, which may be especially useful for visceral
cancers that are not amenable to routine biopsies.

Patients and Methods: We isolated shed exosomes in biofluids from three patients with
pancreaticobiliary cancers (two pancreatic, one ampullary). We performed comprehensive
profiling of exoDNA and exoRNA by whole genome, exome and transcriptome sequencing
using the Illumina HiSeq 2500 sequencer. We assessed the feasibility of calling copy number
events, detecting mutational signatures and identifying potentially actionable mutations in
exoDNA sequencing data, as well as expressed point mutations and gene fusions in exoRNA
sequencing data.

Results: Whole exome sequencing resulted in 95 to 99% of the target regions covered at a
mean depth of 133 to 490x. Genome-wide copy number profiles, and high estimates of tumor
fractions (ranging from 56 to 82%), suggest robust representation of the tumor DNA within the
shed exosomal compartment. Multiple actionable mutations, including alterations in NOTCH1
and BRCA2, were found in patient exoDNA samples. Further, RNA sequencing of shed
exosomes identified the presence of expressed fusion genes, representing an avenue for
elucidation of tumor neoantigens.

Conclusions: We have demonstrated high-resolution profiling of the genomic and
transcriptomic landscapes of visceral cancers. A wide range of cancer-derived biomarkers
could be detected within the nucleic acid cargo of shed exosomes, including copy number
profiles, point mutations, insertions, deletions, gene fusions and mutational signatures. Liquid
biopsies using shed exosomes has the potential to be used as a clinical tool for cancer
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diagnosis, therapeutic stratification, and treatment monitoring, precluding the need for direct
tumor sampling.
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Patients and samples
Three patients with pancreatobiliary cancers were included in our comprehensive liquid biopsy
study (supplementary Table S1), and each was consented following institutional review board
approval (PA15-014). Case LBx01 is a 57-year old man who initially presented with stage IIA
PDAC. He received neoadjuvant gemcitabine-based chemoradiation therapy with subsequent
R0 resection and adjuvant gemcitabine. He was diagnosed with multifocal pulmonary
recurrence on surveillance imaging 16 months after completion of adjuvant therapy, and
confirmed pathologically by thoracoscopic wedge resection of one dominant lesion. Whole
exome and RNA sequencing were performed on the metastatic lung tissue (by Dr. Arul
Chinnaiyan at the University of Michigan). Thirteen months subsequent to surgical
metastatectomy, the patient then developed evidence of pleural effusion, and therapeutic
thoracentesis yielded 800 mL of pleural fluid from which shed exosomes were isolated and
downstream whole genome, exome and RNA sequencing analyses were performed. Case
LBx02 is a 68-year old woman with PDAC primary and hepatic metastases. Thirty mL of whole
blood were collected via standard blood draw prior to initiation of chemotherapy and exosomes
were isolated for subsequent tumor profiling analyses. Case LBx03 is a 74-year old man who
underwent an upfront pancreaticoduodenectomy for an ampullary mass. Final pathology
confirmed a stage IIB pancreatobiliary type adenocarcinoma of the ampulla. He received
platinum-based adjuvant chemoradiotherapy and had no evidence of recurrence 5 months after
completion of definitive therapy. Thirty mL of peripheral whole blood were collected upon the
patient’s referral to MD Anderson Cancer Center after resection, but prior to beginning any
adjuvant therapy. Plasma exosomes were isolated for tumor profiling analyses.
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Introduction

For many visceral cancers, such as pancreatic ductal adenocarcinoma (PDAC), the availability
of tissue-based companion diagnostics may be limited or precluded secondary to clinical
factors such as tumor location, amount of tumor tissue sampled or procedure-associated risk,
hindering the progress of precision medicine (172). Relatively non-invasive liquid biopsies offer
a promising alternative for tumor characterization and disease monitoring. To this end, several
investigators have identified tumor-specific genetic mutations in patient plasma-derived
circulating cell-free DNA (cfDNA) including activating mutations in KRAS, BRAF, EGFR and
other cancer genes using highly-sensitive targeted approaches such as digital PCR and
targeted amplicon sequencing on cfDNA (173-175). Recently, whole genome and exome
sequencing have been performed using the cfDNA of plasma samples in an effort to estimate
tumor copy number profiles and identify actionable mutations in a more agnostic manner (45,
176, 177). However, the extensively fragmented nature of cfDNA in circulation makes it difficult
for this format to become generalizable in the context of genomic characterization of tumors
through current next-generation sequencing (NGS) platforms (85). This limitation is even more
profound in the context of circulating RNAs, where profiling is essentially restricted to small
microRNAs, due to extensive fragmentation of coding transcripts (86, 87, 178).

Exosomes are 40-150 nanometer-sized membrane-bound extracellular vesicles that arise by
specific endosomal biogenesis pathways (179). Functionally, exosomes have been shown to
influence the tumor microenvironment as vehicles for cell-cell communication in cancer,
harboring a diverse repertoire of molecular cargo that are shielded from degradation in
circulation and that are representative of their originating cells (67, 179, 180). Therefore, the
quality, diversity and tumor-specific nature of exosomal DNA (exoDNA), and exoRNA provide a
potentially favorable alternative compared to cell-free nucleic acids for comprehensive tumor
profiling at high-resolution. Indeed, recent publications have shown that exosomes contain
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genomic representations of high molecular weight (HMW; >10kb), double-stranded fragments
of DNA (70, 71).
We sought to assess the feasibility and potential clinical utility of characterizing the entire
genomic and transcriptomic profiles of visceral cancers using the nucleic acid cargo within shed
exosomes obtained from a single specimen of patient biofluid. We show, for the first time, that
it is possible to perform integrative profiling of tumors from shed exosomes by analyzing the
DNA and RNA cargo using standard NGS platforms, and that this approach has the potential to
circumvent the need for direct tumor sampling in visceral cancers.
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Results

Plasma and pleural effusion exosome isolations are enriched with high molecular weight
double-stranded genomic DNA
Shed exosome populations were confirmed by scanning electron microscopy and transmission
electron microscopy (Figures 16A and B). Nanoparticle-tracking analysis (Particle Metrix Inc.)
confirmed the presence of exosome-sized vesicles in the liquid biopsy of all three patients
(Figure 16C). Expression of canonical exosome surface markers, including the tetraspanin
CD63 by flow cytometry and CD9, CD63, CD81 and HSP70 by western blots (Figure 16D and
E) also established the presence of exosomes in our isolations. Extraction of exoDNA revealed
quantifiable HMW double-stranded DNA (dsDNA; >10kb in size) as seen in Figure 16F.

Exosomes contain a large fraction of tumor DNA
KRAS mutant allele frequency (MAF) was determined using the KRAS multiplex screening
assay and droplet digital PCR platform (ddPCR, BioRad Technologies, see Supplementary
Methods) demonstrating tumor presence in our exosome isolations (Figure 16G). PCR-based
analysis of mutant KRAS and BRCA2 pre- and post-whole genome amplification demonstrated
conserved MAFs (Figure 17). In addition, genome wide copy number profiling identified
somatic copy number changes across the genomes of each patient. High estimates of tumor
fractions ranging from 56 to 82% for each liquid biopsy sample suggests stout representation of
the tumor within the circulating exosomes of each patient.
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Figure 16 Characterization of exosomes isolated from liquid biopsies
A: Scanning electron microscopy of exosomes from plasma PDAC sample.
B: Illustrates that vesicle diameters are frequently only 5- to 10-fold greater than the
bilayer thickness, which is typical of the internal vesicles of multivesicular bodies.
C: Size and counts of particles per ml biofluid (plasma or pleural effusion) as measured
by nanoparticle tracking analysis. The size distribution is in the range of exosomes (40150 nm) and other microvesicles.
D: Enriched exosomes were captured using the CD63+ Dynabeads. Dynabead bound
exosomes were stained with PE Mouse Anti-Human CD63. Isotype control was stained
by Simultest IgG2a/IgG1. The gating strategy for single beads is shown (left) with
effective capture of CD63+ exosomes as demonstrated by the shift in fluorescence
(right).
E: Western blots for exosomal markers (CD81, CD63, CD9 and HSP70) show that bands
at the expected size were observed for multiple markers. Pa04C protein whole cell lysate
is used as a protein expression control and human serum-derived exosomes (+ cont.) is
use for the exosomal marker control.
F: Example of an exoDNA obtained from a clinical PDAC patient. Image shows the
performance in the electropherogram of a HMW exoDNA pre and post WGA. Exosomes
contain HMW DNA (>10kb in size), as determined using an Agilent tape Station 2200.
AUC also show HMW DNA concentration higher than 60ng per microliter from a 20
microliter

total

volume,

enough

DNA

for

NGS

on

clinical

samples.

G: ExoDNA was isolated from plasma of an advance case of PDAC. The sample on top
comes from an individual with advanced PDAC (LBX03). Using ddPCR on 1μL of
exoDNA eluate, we are able to detect mutant KRAS, blue dots (mutant droplets), green
dots represent wild type sequences. Allele frequency of KRAS genes is preserved pre(42%) and post-whole genome amplification (37%) (lower panel).
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Figure 17 Sanger sequencing validation of exoDNA mutation
BRCA2 Sanger sequencing validation in the pre- and post-amplified exoDNA shows
preservation of allele frequencies approximately 80-90% pre and post-amplification.
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ExoDNA is representative of the entire human genome
Whole genome sequencing covered 65 to 91% of the human genome at a mean depth of 12 to
35x at high sequencing quality with 88.2 to 92.5% of bases having greater than or equal to
sequencing quality scores of Q30. Exome sequencing covered 95 to 99% of the targeted
genome (54 megabases) with at least one read at a mean depth of 133 to 490x with 73 to 96%
being covered by at least 10 reads. Ninety to 94.6% of bases represented high quality sequence
suggesting that exoDNA in our samples is representative of the entire human genome.

Comprehensive profiling of tumors using exoDNA and mRNA
LBx01: Tumor profiling using pleural effusion exosomes from a patient with pancreatic
ductal adenocarcinoma with previously resected lung metastasis
LBx01 is a patient PDAC, who underwent a thoracoscopic resection of a suspicious pulmonary
nodule, subsequently confirmed to be metastasis. Fifteen months later, he developed a pleural
effusion, which contained less than 1% malignant cells on cytospin, per final cytopathology
report. A deep NGS assay performed on the pleural fluid cytospin failed to detect any evidence
of tumor DNA. In contrast, abundant cancer-derived exosomes were present in the pleural fluid
even with the marked paucity of cancer cells. The pleural effusion exoDNA had a computationally
estimated tumor fraction of 82% (95% confidence region (CR) of 81-83%) and a mean genome
copy number of 2.57. The exoDNA tumor fraction estimate was higher than that compared to
the previously resected metastatic lung tissue (23%, 95% CR, 22-24%). The exoDNA mutation
rate was estimated at 341 mutations/Mb compared to 2.06 mutations/Mb in the metastatic lung
tissue DNA 15 months prior to the liquid biopsy sampling. This substantially higher mutational
load is not surprising given the time between metastectomy and manifestation of pleural effusion,
and the multi-drug cytotoxic chemotherapy regimen administered to the patient.
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Potentially actionable mutations are listed in Table 8. We considered mutations to be potentially
actionable if they are either putative drivers (recurrently mutated in COSMIC (100)) that could be
monitored over the course of patient management, or COSMIC mutations that reside in genes
associated with a clinical trial or cancer drug (see Supplemental Methods). Mutations in KRAS
and TP53 were identified in both the lung metastatic tissue and the subsequent pleural effusion.
Mutations likely representative of progression include those in APC and CHEK2. The metastatic
lung tissue harbored a mutation signature with peaks at C-to-T base substitutions that are
consistent with Signature 1 of the COSMIC mutational signatures (Figure 18C), a common
cancer signature proposed to be involved in spontaneous deamination of 5-methylcytosine (100,
113). The exoDNA mutational signature deviates from this, which suggests that additional
mutational processes may have contributed to tumor progression, possibly driven by cytotoxic
chemotherapy.
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ExoDNA copy number profiling showed that 27% of the genome exhibited copy number variation
(Figure 18A). This included amplification of MYC (copy number (CN)=3; P-val=1.3e-72), KRAS
(CN=6; P=2.7e-11), EGFR (CN=3; P=1.3e-138) and ERBB2 (CN=5; P=6.1e-10).

ERBB2

amplification, in particular, was also identified in the previously resected lung metastasis, albeit
at a lower copy number. We confirmed the amplification and overexpression, respectively,
ERBB2 in both exoDNA and exoRNA, where the estimated copy number was 5 and ERBB2 was
over-expressed at 85.13 transcripts per million (TPM) which represents a 3.62 times higher
expression compared to normal pancreas tissue (23.52 TPM - the median ERBB2 expression in
normal pancreas tissue identified from the Genotype-Tissue Expression (GTEx) project (181)).
A key advantage of exoRNA (in contrast to cell free nucleic acids) is the preserved quality of
transcripts that allows for assessment of an aberrant transcriptome in the same liquid biosample
from which the genomic landscape is derived. As exemplified with ERBB2, cross comparison of
exoDNA and exoRNA data permits precise delineation of the oncogenic targets of genomic copy
number aberrations.

Another potential clinical benefit of this approach is identification of

expressed neoantigens from the tumor, be it missense mutations, or unique cancer-derived
fusion transcripts, which can serve as the basis for identification of neoantigen-targeted humoral
or cellular immune responses (182, 183). For example, the exoRNA confirmed presence of a
KRAS G12D mutation in the transcriptome (Figure 18B). Furthermore, 87.8% of protein-coding
transcripts were expressed (having greater than or equal to 2 TPM) and 40 putative expressed
gene fusions were identified (Figure 18D), though no delineated cancer signaling pathways were
overrepresented in the exoRNA data.
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Figure 18 LBx01 tumor profiling

(A) Copy number profile comparison between the metastatic lung tissue (top) sampled 15 months
before the pleural effusion exoDNA (bottom). The cancer-related genes on the light-red vertical
bars have copy number gains and those on the light-blue vertical bars have copy number losses,
where the numbered labels represent the estimated copy numbers. The yellow vertical bar
annotates putatively actionable copy number variations (CNVs) (e.g. ERBB2). The arrow to the left
depicts the progression of cancer-associated CNVs between the 2 time points. These happen to
all be amplifications, which were also confirmed to be upregulated in the exoRNA compared with
that in the metastatic lung tissue RNA-seq.
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(B) Mutant KRAS was identified in the mRNA (RNA sequencing) as well as DNA (exome and
genome sequencing) of the pleural effusion exosomes. (C) Mutational signature of the plasma
exosomes derived from exome sequencing (top) and genome sequencing (middle) compared with
the mutational signature of the metastatic lung tissue (bottom). (D) Circos plot illustrating putative
gene fusions (blue), lung metastatic copy number profile (inner-most ring), pleural effusion
exosomes copy number profile (second inner-most ring) and gene aberrations. Mutations seen in
the pleural effusion are black and those seen in both the metastatic lung tissue and pleural effusion
are in bolded black.

LBx02: Tumor profiling using blood-derived exosomes of a pancreatic ductal
adenocarcinoma patient
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LBx02 is a treatment-naïve patient with PDAC and hepatic metastases. The plasma exoDNA
estimated tumor fraction was 56% (95% CR of 54-57%) with a mean genome copy number of
2.12. Copy number profiling showed that 9% of the genome exhibited copy number variation
(Figure 19A). This included amplification of MYC (CN=13; P=4.7e-08), KRAS (CN=3; P=6.5e24) and loss of TP53 (CN=1; P=3.6e-39). Potential actionable mutations (Table 9) include
mutations in ERBB2, KRAS, NRAS and NOTCH1 (in practice, KRAS or NRAS mutations are not
strictly actionable, although many commercially available or academic center-initiated
sequencing panels list them as such). The exoDNA exhibited a mutation rate of 77 mutations/Mb
and a profile resembling Signature 1 of the COSMIC mutational signatures (Figure 19B) (100,
113).
Approximately 9% of protein-coding transcripts were expressed in the exoRNA and 16 putative
expressed fusions were identified (Figure 19C).

The mTOR signaling pathway was over-

represented in the exoRNA transcripts (Benjamini-Hochberg P=0.027).
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Figure 19 LBx02 tumor profiling
(A) Copy number profile of the plasma exoDNA. (B) Mutational signature of the pleural effusion
exosomes derived from exome sequencing (top) and genome sequencing (bottom). (C) Circos plot
illustrating putative gene fusions (blue), plasma exoDNA copy number profile (inner-most ring) and
potential actionable genes (blue, deletions; red, amplifications; black, somatic point mutations).
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LBx03: Tumor profiling using blood-derived exosomes of an ampullary carcinoma patient

identifies an unexpected therapeutic vulnerability
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LBx03 plasma exoDNA had an estimated tumor fraction of 82% (95% CR of 81-84%) and a mean
genome copy number of 2.5. Copy number profiling showed that 53% of the genome exhibited
copy number variation (Figure 20), which suggests the presence of an “unstable” genome
phenotype (40). Copy number aberrations include amplification of MYC (CN=4; P=6.7e-129)
and KRAS (CN=3; P=3.8e-69). The exoDNA mutation rate is estimated at 125 mutation/Mb
exhibiting a relatively large proportion of C-to-A and C-to-T base substitutions (Figure 20B).
Several potentially actionable mutations were identified (Table 10) including an unexpected
somatic mutation of BRCA2, which was not present in the germline DNA. Specifically, the
BRCA2 V3091I mutation has previously been reported as conferring a homologous
recombination defect in cancer cells (184). Three lines of evidence suggest that this BRCA2
mutation is indeed pathogenic: first, the high MAF in exoDNA, underscoring its “driver” status,
second the “unstable” genome phenotype on genome-wide copy number assessment (40), and
third, the exceptional response to a platinum-containing adjuvant regimen that this patient has
had to date (although the overall follow-up period remains limited).

In the exoRNA, 16.6% of protein-coding transcripts were expressed, including 40 putative
expressed gene fusions (Figure 20C). No cancer signaling pathways were overrepresented in
the exoRNA data.
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Figure 20 LBx03 tumor profiling
(A) Copy number profile of the plasma exoDNA. (B) Mutational signature of the plasma
exosomes derived from exome sequencing (top) and genome sequencing (bottom). (C)
Circos plot illustrating putative gene fusions (blue), plasma exoDNA copy number profile
(inner-most ring) and potential actionable genes.
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Discussion

We have demonstrated the feasibility of using peripheral blood and pleural effusion based liquid
biopsies to comprehensively profile the genomes and transcriptomes of deeply located visceral
cancers for which traditional tissue biopsies may be difficult, risky, or unachievable in lessspecialized centers. In addition, exosome-based liquid biopsy results demonstrate the potential
for identifying unexpected therapeutic vulnerabilities. Of particular importance regarding patient
LBx03, is the presence of a BRCA2 mutation, which has been shown to predict responsiveness
to platinum-based chemotherapies. Currently, several clinical trials are ongoing that incorporate
platinum-based regimens of PARP inhibitors in PDAC patients with such DNA damage repair
defects (185).

In addition to identifying actionable mutations at the time of presentation,

exosome-based liquid biopsies provide an opportunity to identify new therapeutic vulnerabilities
that emerge over the course of treatment, or elucidate potential mechanisms of resistance to
administered targeted therapies.

For example, at the time of metastectomy of the lung

metastasis from LBx01, the patient was found to have evidence of ERBB2 amplification in the
pulmonary nodule, leading to subsequent attempt of targeted therapy with Trastuzumab.
However, no meaningful response was found to the agent. Two months following completion of
this therapy, subsequent liquid biopsy from this patient confirmed the ERBB2 amplification, as
well as the emergence of an EGFR amplification, which might represent a clonal selection in
response to the trial of a targeted agent (186). Liquid biopsy in this patient far exceeded standard
of care lab metrics where less than 1% tumor cells were detected in the pleural effusion,
precluding further analysis. Cancer-derived exosomes were able to enrich for the genetic makeup of the local tumor tissue, recapitulating the molecular identity of the diseased lung. It is
important to note that such “serial” sampling of the tumor genomic landscape, while possible in
superficial cancers like melanomas, is almost unheard of in visceral malignancies, due to
logistical or reimbursement limitations.
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While cfDNA platforms can certainly elucidate limited panels of genomic abnormalities and even
map the emergence of resistance mechanisms during the course of targeted therapies,
exosome-based liquid biopsy approaches have the additional benefit of being able to
comprehensively profile the cancer transcriptome from the same biosample. In particular, the
ability to identify expressed neoantigens (point mutations or fusion transcripts) represents an
avenue to interrogate the humoral or cellular responses to such neoantigens in visceral cancers
(182, 184). For example, emerging “personalized” adoptive T cell therapies require elucidation
of cancer-specific neoantigens that are expressed and processed in an HLA context (187).
Typically, this requires a tissue biopsy and RNA profiling of the tumor. Exosome-based liquid
biopsy can identify such expressed neoantigens without the need for tissue sampling, and
moreover, map the response to immunotherapy through quantitative estimates of neoantigen
load in circulation. In addition, since the peripheral blood is a sampling of all body tissues, this
genetic analysis presumably has the power to characterize the patient’s entire tumor burden:
primary tumor and any metastatic disease. This is of particular importance when considering
that primary tumors and associated metastases are of a heterogeneous genetic makeup with
compounded temporal heterogeneity (188).

Our study is not without limitation. Conceptually, many will desire to see liquid biopsy detected
mutations validated in primary tissue. For visceral cancers, the acquisition of such tissues may
be limited and localized, thus detection of mutations for validation may not be ideal. Of note, our
mutation rates of 341, 77 and 125 mutations/Mb are substantially higher than the average of 2.64
mutations/Mb (range 0.65-28.2) estimated by Waddell et al (40) from PDAC tissue whole genome
sequencing. We suspect that a large degree of this discrepancy is due to exoDNA representing
tumor heterogeneity at a level that is not attainable through tissue sequencing. A potential
strategy to confirm these liquid biopsy findings is to compare serial samples in the same patient,
to validate over time the identification of mutations at varying allelic frequency. Such serial
profiling is the subject of further study. Nonetheless, our proof of concept results demonstrate
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that seamless coordination between clinical and research efforts can produce a workflow from
blood draw to sequencing results in a period of 14 days, acquiring results in a clinically relevant
timeframe for patients with visceral cancers.
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Chapter 6 - Surfaceome profiling enables isolation of cancer-specific exosomal cargo in
liquid biopsies from pancreatic cancer patients

With permission this chapter is based upon “Castillo, J*., V. Bernard*, F. A. San Lucas, K.
Allenson, M. Capello, D. U. Kim, P. Gascoyne, F. C. Mulu, B. M. Stephens, J. Huang, H. Wang,
A. A. Momin, R. O. Jacamo, M. Katz, R. Wolff, M. Javle, G. Varadhachary, Wistuba, II, S. Hanash,
A. Maitra, and H. Alvarez. 2017. Surfaceome profiling enables isolation of cancer-specific
exosomal cargo in liquid biopsies from pancreatic cancer patients. Annals of oncology : official
journal of the European Society for Medical Oncology / ESMO. (*First authorship shared)”
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Abstract
Background
Detection of circulating tumor DNA (ctDNA) can be limited due to their relative scarcity in
circulation, particularly while patients are actively undergoing therapy. Exosomes provide a
vehicle through which cancer-specific material can be enriched from the compendium of
circulating non-neoplastic tissue-derived nucleic acids. We performed a comprehensive
profiling of the pancreatic ductal adenocarcinoma (PDAC) exosomal “surfaceome” in order to
identify surface proteins that will render liquid biopsies amenable to cancer-derived exosome
enrichment for downstream molecular profiling.

Patients and methods
Surface exosomal proteins were profiled in 13 human PDAC and 2 non-neoplastic cell lines by
liquid chromatography-mass spectrometry. A total of 173 prospectively collected blood samples
from 103 PDAC patients underwent exosome isolation. Droplet digital PCR (ddPCR) was
used on 74 patients (136 total exosome samples) to determine baseline KRAS mutation call
rates while patients were on therapy. PDAC-specific exosome capture was then performed on
additional 29 patients (37 samples) using an antibody cocktail directed against selected
proteins, followed by ddPCR analysis. Exosomal DNA in a PDAC patient resistant to therapy
were profiled using a molecular barcoded, targeted sequencing panel to determine the utility of
enriched nucleic acid material for comprehensive molecular analysis.

Results
Proteomic analysis of the exosome “surfaceome” revealed multiple PDAC specific biomarker
candidates: CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE and HIST2H2BF. KRAS
mutations in total exosomes were detected in 44.1% of patients undergoing active therapy
compared to 73.0% following exosome capture using the selected biomarkers. Enrichment of
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exosomal cargo was amenable to molecular profiling, elucidating a putative mechanism of
resistance to PARP inhibitor therapy in a patient harboring a BRCA2 mutation.

Conclusion
Exosomes provide unique opportunities in the context of liquid biopsies for enrichment of
tumor-specific material in circulation. We present a comprehensive surfaceome
characterization of PDAC exosomes which allows for capture and molecular profiling of tumorderived DNA.
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Introduction
An emerging body of literature demonstrates that comprehensive characterization of cancer
genomes has both diagnostic and prognostic utility, and may provide insights into formulating
individualized treatment strategies (40, 80). However, even with large scale sequencing efforts,
accessibility of tumor tissue is often limited by both patient- and/or system-centered factors.
Tissue sampling of pancreatic ductal adenocarcinoma (PDAC) may be limited to an initial
diagnostic FNA, while risk of biopsy, locally destructive therapies, cost or facility capabilities may
limit further sampling efforts. “Liquid biopsy” is a less invasive strategy for tumor sampling, which
may circumvent the need for tissue biopsy while still affording high resolution profiling of the
genomic landscapes of visceral cancers. Within the field of liquid biopsy, tumor-derived
extracellular vesicles (EVs) such as exosomes, are a source of high-quality nucleic acids for
molecular characterization with inherent utility for diagnostic and therapeutic purposes (154).

Exosomes are nanometer-sized membrane-limited extracellular vesicles that arise from
endosomal biogenesis pathways and serve as critical means of cell-cell communication (189).
Tumor-derived exosomes contain membrane-tethered proteins, microRNAs, and as recently
demonstrated, entire genomic complements of DNA (exoDNA) (70, 71, 190, 191). Exosomes
are shed from both tumor and non-neoplastic cells into the peripheral circulation. Therefore, one
of the potential pitfalls of utilizing exosomes, and essentially any liquid biopsy component
including circulating tumor DNA (ctDNA), as a surrogate for the tumor genome is that genetic
information obtained from such exosomes will be diluted in large part with the DNA of non-cancer
cell-derived exosomes. Exosomal surface biomarkers provide a means to separate cancer from
non-cancer derived exosomes through the use of bead-based selection of such markers. While
exosomes are known to express tetraspanins such as CD63, CD9, and CD81, these biomarkers
are not specific to cancer-derived exosomes. Specific markers to distinguish normal and cancer
tissue derived exosomes is an area of active research, particularly in PDAC where the use of
such biomarkers have great potential in early disease detection (138, 192). Here, we identify a
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panel of PDAC-specific exosomal surface proteins, demonstrate the ability to enrich for PDACderived exosomes in circulation using these identified proteins, and then show the feasibility of
mutation profiling of enriched exoDNA samples through next-generation sequencing (NGS).

Results

“Surfaceome” profiling of exosomes
Surface and cargo exosomal proteins were profiled in 13 human PDAC cell lines, and 2 nonneoplastic cell lines (HPNE and CAF19) through liquid chromatography-mass spectrometry
(MS). Proteomes from exosome surface and cargo were fractionated at an intact protein level
and then subjected to trypsin digestion and MS-based analysis. A total of 7086 proteins
(corresponding to 3663 gene symbols) were identified. Requiring expression on the surface of
at least 3 samples (i.e. the proposed exosomal “surfaceome”) demonstrated the presence of
canonical proteins universally expressed in exosomal populations including CD81, CD9, and
TSG101 resulting in 1057 proteins (corresponding to 482 genes;). In order to identify a panel of
PDAC-specific surface exosomal markers, resulting “surfaceome” proteins that were found to be
expressed in at least 3 PDAC cell lines with a maximum of 1 spectral count being expressed in
non-neoplastic cell lines were considered candidate PDAC-specific exosomal surface
markers. In addition, we annotated these candidates using the extracellular vesicle database
ExoCarta (database of exosomes proteomics, including data from 160 exosome experiments
and 166 samples based on mass spectrometry analyses), which contains human exosome
protein profiles from normal and cancer tissue sources to effectively assess the absence of our
candidate proteins from vesicles of non-neoplastic origin. Further curation and validation of these
biomarkers was prioritized based on biological rationale and availability of targeting antibodies
(Figure 21).
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Figure 21 Cancer-specific exosomal biomarker selection and validation
(A) Heat map representation of proteins that are expressed on the surface of pancreatic
ductal adenocarcinoma exosomes that are not expressed (or expressed at very low levels) on
the surface of HPNE and CAF19 exosomes. (B) Western blot validation of identified candidate
biomarkers: protein expression analysis of cell lysates (left) compared with exosomes (right)
of neoplastic (Pa01C, Pa03C, and Pa04C) and non-neoplastic (CAF19 and SC2) cell lines.
CD63 and TSG101 are used as antibody controls for identification of exosome populations.
Most selected biomarkers show enriched specificity towards being present in cancer
exosomes versus normal exosomes.
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Biomarker validation
Candidate proteins were validated through western blot analysis of PDAC cell line derived
exosomes from Pa01C, Pa03C, and Pa04C (Figure 21). Non-neoplastic cell lines CAF19 and
SC2 were used as controls. Candidate biomarkers were detected within protein lysates of cell
lines with varying degrees of sensitivity and specificity, but were effectively enriched within the
exosome protein fractions. In other words, protein biomarkers such as CD151 and HistoneH2B
(H2B) are found in the protein lysates from all cell lines, including non-neoplastic cell lines, but
are only found within exosomes derived from PDAC cell lines. On the other hand, LGALS3BP is
present in all exosomal populations, but is overexpressed in tumor derived exosomes when
compared to non-neoplastic sources. In contrast, the recently published PDAC exosomal
biomarker glypican-1 (GPC1), did not demonstrate significant expression in tumor-derived
exosomes and in fact appeared to be selectively expressed in non-neoplastic sources when four
separate GPC1 antibodies were tested, including the originally reported clone (ThermoFisher,
PA5-28055) (Figure 22) (138). This profiling analysis led to a final antibody cocktail targeting
the following candidate biomarkers: anti-CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE and
HIST2H2BF, respectively used for subsequent enrichment studies.
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Figure 22 Western blot analysis of GPC1
Western blot analysis of four GPC1 commercially available antibodies which we
attempted to validate for tumor exosome specific detection. No protein was seen at the
expected size range to suggest that this biomarker could be cancer exosome specific.

Validation of capture assay in clinical samples
Following selection of our candidate biomarkers, we designed an immunocapture pulldown assay
to specifically capture enriched populations of cancer-derived exosomes. Aldehyde/sulfate latex
beads were coated with the five antibodies of choice as a cocktail targeting the identified and
validated exosome protein biomarkers. In this fashion, we selectively enriched for cancer derived
exosomes by pulling down only those extracellular vesicles exhibiting the above biomarkers from
the overall shed exosome population. By using PE-CD63 (a pan-exosome marker) fluorescence
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signal as a surrogate for overall effective exosome capture, we then measured the sensitivity
and specificity of the enrichment method. Specifically, by selecting for exosomes using antiCD63, we are able to detect the presence of exosome populations in all of our cell line isolates
(Figure 23), but effectively avoid non-specific binding of exosomes using our blocking buffer as
shown by the lack of fluorescence (Figure 23C). Finally, when the beads are coated with our
biomarker antibodies of interest, specific capture of cancer derived exosomes compared to nonneoplastic derived exosomes is apparent (Figure 23D).
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Figure 23 Exosome capture assay methodology

(A) Pulldown assay incubating aldehyde/sulfate latex beads with the cocktail of antibody
markers of choice. The aldehyde groups grafted onto the surface of these beads enables
facile coupling of proteins to the surface of the particle. Following coating of the bead with
the antibody of choice, non-coated surfaces are blocked with a BSA/Glycine buffer to
prevent nonspecific binding of exosomes. Beads are then incubated with exosomes
overnight resulting in an enriched population of vesicles based on the marker of choice
which is amenable to downstream molecular analysis. (B) Pulldown assay is able to
capture exosomes with minimal unspecific binding to first determine effective capture of
exosomes using our assay, beads coated with CD63 antibody were incubated with either
neoplastic (Pa04C) or non-neoplastic (SC2) derived exosomes and subsequently tagged
with a CD63-PE conjugated secondary antibody (a pan-exosome marker). Results based
on flow cytometry show effective capture of exosome populations using this assay.
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(C) To confirm no non-specific binding of exosomes and effective blocking strategy, beads
were first incubated with blocking buffer (BSA+Glycine), and then underwent subsequent
incubation with the antibody of choice followed by cell line derived exosomes. The
resulting beads were then treated with the CD63-PE conjugated secondary antibody and
profiled using flow cytometry. This demonstrates that no exosomes were detected being
bound to the beads, confirming no non-specific exosome binding. (D) Specific capture of
PDAC cell line exosomes using this methodology was then validated in a representative
candidate pulldown markers (EPCAM), demonstrating that beads specifically capture
exosomes only when incubated with those coming from PDAC cell lines (Pa04C and
Pa03C), and not non-neoplastic cell lines (HPNE, SC2, CAF19).
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We next aimed to implement our enrichment methodology for PDAC-derived exosomes on
patient plasma samples to determine its effectiveness at detecting tumor derived DNA during
therapy (Table 10).

Table 10 Patient characteristics for exosome capture

Characteristics

Total Samples
Age (Years)
Average
Median
Range
Sex
Male
Female
Clinical Staging
Resectable

Locally Advanced
Metastatic

Stage IA
Stage IB
Stage IIA
Stage IIB
Stage III
Stage IV

Total
Exosomes
Control
Cohort
136

Captured
Exosomes
Cohort

61.4
61
(36-88)

62.4
62
(37-88)

86
50

23
14

7
8
26
11
30
54

2
6
4
5
8
12

37

Detection rates for mutant KRAS exoDNA in a control cohort of 136 prospective samples that did
not undergo capture enrichment (total exosomes) taken during active chemotherapeutic
intervention was 32.7% (17/52), 50% (15/30), and 51.8% (28/54) in resectable, locally advanced,
and metastatic disease, respectively as defined by American Joint Committee on Cancer
guidelines (Figure 24). In 37 samples that underwent exosome capture as previously described,
our mutation detection rate increased to 70.6% (12/17), 71.4% (5/7), and 76.9% (10/13) in
resectable, locally advanced, and metastatic disease, respectively. Of note, these
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Figure 24 exoDNA KRAS mutant detection in circulation
(A) Percent of patients with detectable mutant KRAS in exoDNA among those patient samples
that did and did not undergo capture enrichment. When comparing the percentages of patients
with detectable KRAS in the pulldown-cohort versus the total exosome cohort, the pulldown-cohort
consistently detects KRAS in a higher proportion of patients across stages. This increase in callrate was statistically significant in resectable patients (P = 0.024) where pulldown samples were
4.11 (95% CI: 1.14–17.19) more likely to have KRAS detected. (B) KRAS mutant allele frequency
(MAF) comparisons of captured exosomes versus total exosomes, there was a statistically
significant difference showing increased KRAS MAFs from the captured exosomes for resectable
and metastatic patients (P = 0.003 and 0.015, respectively, using one-sided Wilcoxon Rank Sum
tests).
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detection rates reach the theoretical upper limit of detection of our ddPCR multiplex assay which
can detect up to 80% of known KRAS mutations found in PDAC (37). This suggests that most
patient undergoing therapy have tumor-derived material in circulation that is typically
overwhelmed by non-neoplastic tissue derived exosomes. Harvested exoDNA from both
protocols yielded an average of 19.17ng (0.11-125.72ng) and 24.13ng (0.12-636.00ng) for
captured exosomes and total exosomes, respectively. Overall positive call rate among all
combined patients is associated with the pulldown cohort (p-val = 0.002) where a pulldown
sample is 3.28 (95% CI: 1.41 - 8.19) times more likely to have KRAS detected. Importantly,
exosome capture not only increases the proportion of cases with detectable mutant alleles, but
also leads to a statistically significant increase in KRAS MAF within each category, serving as a
surrogate for tumor enrichment capability (Figure 24B).

Enriched cancer-specific exosomal cargo is amenable to comprehensive molecular
profiling by NGS
A metastatic PDAC patient who underwent prior tumor resection, and subsequently developed
liver metastasis underwent liquid biopsies for exosome isolation. The emergence of metastasis
corresponded with clinically detectable resistance to a Rucaparib (PARP1 inhibitor) clinical trial
which the patient was stratified into due a somatic frameshift BRCA2 (L583*) mutation with
associated loss of heterozygosity. Plasma-derived exosomes were isolated and profiled for
KRAS mutant detection revealing an increase in KRAS mutant burden during disease
progression (Figure 25). In an on-treatment blood draw where no exoDNA mutant KRAS was
detected based on ddPCR, we subsequently attempted exoDNA enrichment resulting in an
increase in mutational KRAS allelic fraction from 0% to 3.2%. More importantly, the amount of
DNA material was sufficient for subsequent NGS using a molecular barcoding approach. This
resulted in the detection of the known driver mutations that were present in the patient’s original
primary tumor, and subsequently detected in the metastatic liver tissue, including mutations in
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KRAS, TP53, and BRCA2. Notably a secondary mutation in BRCA2 was also detected in liquid
biopsies which was not present in the original primary tissue, likely arising during PARP inhibitor
therapy. This mutation resided immediately prior to exon 10 where the BRCA2 (L583*) mutation
was present allowing for the entire exon to be spliced out and leading to transcription of a full
mRNA molecule. Tumor exosomal DNA enrichment thus allowed us to detect this putative
mechanism of resistance to PARP inhibitor, underscoring the utility of liquid biopsies in facilitating
therapeutic stratification.
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Figure 25 Detection of cancer mutations in capture exosomes through molecular
barcodes
(A) Clinical course of a pancreatic ductal adenocarcinoma patient who underwent prior
pancreatic tumor resection, and subsequently progressed while on Parp-1 inhibitor therapy.
ExoDNA enrichment led to capture of tumor derived material which was not previously
detectable. (B) Relevant mutations found in the metastatic tissue and liquid biopsies 6 months
(lbx_02) and 9 months (lbx_03) after tissue biopsy. Of note is the presence of a
stopgain BRCAmutation (L583*) that was correlated to her prolonged response to PARP1
inhibitor therapy. (C) A subsequent mechanism of resistance was detected in the liquid biopsies
and confirmed in the tissue in the form of a BRCA2 splice site variant which splices out the
aberrant stopgain mutation. SLD sum of the largest dimension; exoDNA MAF represent
the KRAS mutant allele fraction. ABR, abraxane (nab-paclitaxel); CIS, cisplatin; GEM,
gemcitabine.
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Discussion
We have performed proteomic profiling of exosomes isolated from a panel of PDAC cells in order
to identify a candidate list of cancer-specific surface exosomal proteins (the PDAC exosomal
“surfaceome”). We validated the cancer specificity of these exosomal proteins by performing the
same proteomic profiling in non-neoplastic pancreatic cell types, and examining which candidate
proteins were differentially and preferentially expressed by the collective PDAC exosomal
“surfacesome”. The resultant PDAC-exosome specific markers can be exploited using an
immunocapture assay for enrichment of tumor specific material in liquid biopsies. This allows for
subsequent molecular analysis of tumor material with implications for early detection, longitudinal
disease monitoring (especially in low tumor volume settings), and therapeutic stratification during
targeted therapy.

Since it is possible that the exosome “surfaceome” may evolve throughout disease progression
and may, in fact, be a product of the intrinsic heterogeneity found in PDAC, we opted to pursue
a multiplexed panel of antibodies against six candidate biomarkers for validation. These included
CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE and HIST2H2BF. As evidenced by our data,
these biomarkers appear to greatly enhance not only the fraction of patients at each PDAC stage
with detectable mutant molecules, but also the mutant allelic fraction per se at each stage,
suggesting enrichment for the tumor-derived nucleic acid component. The latter has direct
implications for downstream molecular assessment using NGS that can be pursued in liquid
biopsy samples.

Mechanisms of DNA packaging within exosomes remain largely unknown as opposed to the
apoptotic/necrotic pathways that are mostly recognized as sources of ctDNA in circulation. In the
nucleus, histones are essential for chromatin structure and play a crucial role during gene
transcription and silencing. Interestingly, histones have also been found outside the nucleus, in
the cytosol, mitochondria and cell membrane (193). Extrachromosomal Histone-H2B has been
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identified as a cytosolic DNA sensor for aberrant self and non-self double-stranded DNA, which
mediates an innate immune response and co-localizes within the mitochondrial membrane (194,
195). Upon detection of cytosolic DNA, H2B has been described to partially associate with
mitochondria and co-localize with the late endosome marker CD63 (93). Both mitochondria and
endosomes are known to generate multivesicular bodies that can fuse with the cell membrane
and generate exosomes (196). Therefore the relative enrichment of H2B within the exosome
compartment of cancer cells suggests that this protein may be interacting with mutant DNA that
originated in the nucleus and which subsequently becomes packaged within exosomes for
transport.

Not unexpectedly, the other candidate exosomal “surfaceome” proteins identified in our analysis
have been independently implicated in cancer initiation and progression of PDAC. For example,
the extracellular matrix glycoprotein LGALS3BP is overexpressed by neoplastic cells with a role
in promoting cell viability, migration and metastasis, resulting in its role as a potential biomarker
associated with prognosis and response to therapy (196, 197). Other identified biomarkers such
as the tetraspanin family member CD151 have also been implicated in cancer initiation and
metastasis; in fact, exosomal CD151 per se has previously been shown to facilitate metastasis
through induction of epithelial to mesenchymal transition in PDAC cell lines (92). The family of
claudin proteins is involved in the formation of tight junctions, with overexpression of CLDN4
previously described in the context of PDAC (198). Notably, this overexpression was present in
both human archival material and genetically engineered mouse models at the stage of PDAC
precursor lesions (pancreatic intraepithelial neoplasia (PanIN)), with implications for early
detection (199). Finally, expression of epithelial markers in circulation has been best
characterized in the context of circulating tumor cells (CTCs). Specifically, the use of EPCAM to
isolate and quantify CTCs has led to FDA approved prognostic tests in colorectal, breast, and
prostate cancers (200). As the majority of content in circulation is derived from blood components
such as peripheral blood mononuclear cells (PBMCs), the presence of circulating material
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expressing epithelial proteins such as EPCAM are postulated to represent tumor-derived origins.
This is further supported by our own data, which suggest that EPCAM in circulation may
represent a cancer specific exosomal biomarker (201).

Previous work has demonstrated the utility of the biomarker GPC1 as a highly sensitive and
specific exosomal biomarker for detection of PDAC (138). While our proteomics data does
confirm that GPC1 is expressed on the PDAC-derived exosomal “surfaceome”, upon
incorporation of public extracellular vesicle databases, this protein appears to be also enriched
in exosomes originating from normal tissues. Further, our experimental data confirms the
presence of GPC1 in non-neoplastic cell lines including CAF19 and SC2, while not being
expressed within the exosomes of three representative PDAC cell lines following attempted
validation using multiple commercially available antibodies. A recent study by Yang et al also
found that GPC1 as a single exosome marker was not optimal in PDAC plasma samples,
although it could potentially be used as a component of a multi-analyte panel (192). Thus, the
significance of GPC1 in PDAC liquid biopsies will require future clarification.

Among limitations of this study are the fact that we were unable to obtain matched captured and
non-captured total exosome samples from the same patient due to the volumes of plasma
required to pursue both protocols. The purpose of utilizing these volumes (~11.7ml of plasma)
was to have sufficient nucleic acid material for downstream NGS analysis. Additionally, our
relatively small sample size which underwent exosome capture may limit the generalization of
our conclusions and would require further validation in larger cohorts. It would also be prudent to
perform this analysis on a cohort of healthy controls in order to effectively validate the specificity
of our cancer derived exosome capture approach for KRAS mutation detection. Finally, it is
important to note the feasibility of implementing such a protocol in the clinics. Whereas plasma
processing and DNA isolation for ctDNA can be performed within a day, the need to isolate
exosomes using a bead immunocapture based approach followed by DNA isolation would
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require four days in addition to the required infrastructure needed for ultracentrifugation. Although
it is not a significant processing time difference, new exosome isolation approaches are being
developed to decrease cost and increase efficiency of specific exosome capture without the need
for ultracentrifugation. This includes the use of antibody coated chips and microfluidic based
approaches which can capture specific exosome populations of interest (202, 203)

The need to enrich for tumor derived material in circulation is underlined by the difficulties in
detecting rare circulating mutant molecules in a heterogeneous milieu that is typically
overwhelmed by non-neoplastic tissue derived DNA. This is particularly compounded in the
context of patients undergoing therapy where mutant DNA might be at levels that are
undetectable with conventional ultra-sensitive digital PCR techniques. The ability to detect latent
mutant molecules has implications in uncovering emerging mechanisms of resistance or
vulnerability nodes before these become clinically evident, thus allowing for more effective
therapeutic stratification. As typical circulating biomarkers such as ctDNA are not amenable to
enrichment methodologies, we present exosomes as a viable alternative to capture tumor
specific material. This can come in the form of not only DNA, but also mRNA and proteins that
are sourced from the originating tumor cell. Indeed, we have demonstrated how a tumor
enrichment platform can lead to detectable tumor material in those patients initially thought to be
free of circulating mutant molecules. But more importantly, specific tumor exosome enrichment
leads to an augmentation of mutant genomic equivalents that are subsequently amenable to
NGS. For example, in our cohort of resectable patients, 44% of patient samples from total
exosomes had sufficient quantity and quality of DNA to undergo downstream molecular
barcoding (as defined by >1% KRAS mutant AF and >1ng of isolated DNA), compared to 67%
of patient samples that were subject to exosome capture. This enrichment then permits
elucidation of emerging mechanisms of resistance, such as a secondary BRCA2 mutation that
reverts PARP sensitivity, as we have demonstrated in our study.
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Throughout this work, we have demonstrated that both circulating tumor DNA and exosomal
derived DNA are amendable to detection through digital PCR and NGS based methods.
Exosomes provide an interesting alternative and complementary approach to conventional liquid
biopsy compartments such as cfDNA as the surface composition of these extracellular vesicles
can give us information of the type of cell where they came from while their content can give us
insight into the functional state of that cell of origin. Although much work has been done
describing the cargo of these microvesicles including proteins and RNA, the existence of DNA
and how it becomes packaged within the vesicles still remains an area of debate. As opposed to
ctDNA which is a product of rapid cell turnover following apoptosis and necrosis, packaging of
exoDNA would need to occur in viable cells through unknown functional mechanisms. Based on
our observations of the presence of histone components in our exosome proteomics, we had
hypothesized that these were byproducts of extrachromosomal DNA. Histones in themselves
would then serve as cytosolic DNA sensors for aberrant self and non-self double-stranded DNA,
which can co-localize with CD63, a known exosomal marker (93). A related mechanism to
exosomal DNA packaging was more recently elucidated whereby cells utilize exosomes as a
means to eliminate harmful cytosolic DNA and thus preventing activation of DNA damage
response pathways (204). Specifically, Takahash, et al., found that inhibiting exosome secretion
of cells resulted in an increase of cytosolic DNA which was recognized by STING and provoked
a reactive oxygen species dependent DNA damage response. This effect was rescued through
overexpression of cytoplasmic DNases which inhibited STING activity. These results suggest
that exosomes play an important role in maintaining cellular homeostasis by removing aberrant
cytoplasmic DNA. Based on this data, one can then hypothesize that exosomes in general may
contain an enriched pool of aberrant or mutated DNA from cells, suggesting that they may
represent an enriched source of tumor derived material in circulation when compared to cell-free
DNA. This seems to be supported by our work presented in Chapter 3 where presence of KRAS
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mutations was more readily detectable in exosomes compared to cfDNA of matched patient
samples. Additionally, our data in Chapter 4 further demonstrates that in addition to higher
sensitivity of detection of KRAS in circulation, these mutant molecules contained within
exosomes are of higher variant allele frequency when compared to matched ctDNA. Although
this data is of course correlative, it would further support the role of exoDNA as another putative
biomarker amongst liquid biopsies.
The role of liquid biopsies as a field lies in its potential for early detection, prognostication, tumor
monitoring, and therapy guidance. Among this, early detection remains the greatest endeavor,
particularly in pancreatic cancer, where identification of those patients at high risk of developing
or having localized disease can lead to potential curative surgical resection, which would result
in a significant impact on survival in this disease. Unfortunately, several issues must be
considered in developing an early detection assay such as the one proposed for liquid biopsies.
These include: 1. Sensitivity and specificity, 2. Organ specificity, 3. A numbers problem, 4.
Lethality problems, 5. Lead time problem.
In regards to sensitivity and specificity, we’ve demonstrated in Chapter 3 that a significant hurdle
in regards to specificity is that apparently healthy individuals can carry known “driver” mutant
molecules in circulation possibly originating from non-clinically relevant lesions. Thus, the current
strategy used in this work of detecting a single point mutation would not be optimal in the setting
of an early detection screening methodology as a significant number of false positives would
arise. One potential solution for this would be to determine the utility of a panel of gene mutations
or genomic signature that may predict the presence of cancer. In the context of PDAC for
example, this can involve using a panel of the top 4 mutated genes, KRAS, TP53, SMAD4, and
CDKN2A. Detection of 3 or more of these as related to potential driver status may thus increase
the specificity of such an assay. Commercial efforts are currently underway to perform such
analysis on large sets of patients. Most recently, GRAIL has raised more than $950 million to
recruit 120,000 women to perform liquid biopsies at the time of mammography. Their goal is to
develop a signature related to breast cancer that involves gene panel sequencing, whole genome
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sequencing, and methylation status through bisulfite genomic sequencing. If successful, studies
such as these would greatly advance the field of liquid biopsies, as it would support further clinical
utility of these biomarkers, unfortunately, performing such studies will not be feasible among
other cancer types. Additionally, even if successful, implementing such assays in general
populations may not be possible due to cost and suboptimal sensitivity/specificity. Thus, at least
in the case of pancreatic cancer, high risk populations would be best stratified for such studies
including those with a family history of cancer, genetic predisposition syndromes (e.g. BRCA2
mutant status), chronic pancreatitis, smokers, and new onset diabetes.
In the context of organ specificity, utilizing KRAS as an early detection marker will not yield much
information considering it is prevalent in many other cancers including lung, colon, and
pancreatic. Again, the GRAIL study is attempting to overcome this issue by finding a specific
signature correlated to breast cancer through their sequencing strategy. But development of such
tools in other cancers may again not be possible due to cost.
In the numbers problem, it is important to consider that hundreds, maybe thousands of
biomarkers exist today, so how do we go about validating them? We cannot perform $1 billion
experiments every time a new attractive biomarker shows up, so what would be the best strategy
to select those most likely to become effective and through which trials? Additionally, even with
ctDNA, there are many methodologies available today to profile this liquid biopsy compartment,
including digital PCR, whole genome sequencing, and numerous gene panels coupled with
molecular barcodes with undisclosed targeting strategies.
In regards to the lethality problem, it’s of course important to note that even if we can detect
cancer early in general, not all cancers will be lethal. An example being that of prostate cancer,
where most men would die with prostate cancer but not of prostate cancer. But even in the case
of studies such as those by GRAIL, not all ductal carcinomas in situ (DCIS) will develop an
invasive component. In that case, how can we best stratify those patients that are likely to benefit
most from surgical resection in order to circumvent morbidity and costs.
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Finally, by lead time problem we mean, what is the difference in time between a positive test on
a liquid biopsy and a positive result on imaging such as CT or mammography. In the context of
breast cancer, if this is just 1-2 weeks, then is there any real benefit to this new biomarker? In
Chapter 4 we describe an average lead time of 50 days, but considering the rapid clinical
deterioration of pancreatic cancer, can a biomarker such as this be relevant and result in
significant survival benefits? Several studies have attempted to report clinically relevant lead
times such as Tie et al., who describe a lead time to radiological recurrence of colon cancer of 5
months compared to CEA following resection, and Chaudhuri, et al., who describe a lead time of
5.2 months for localized lung cancer which they attribute to the presence of minimally residual
disease (149, 205). Regardless of these findings, a prospective randomized trial validating the
utility of these lead times would need to be conducted.
Ultimately, it is the personal view of this author, that liquid biopsies in the form of circulating tumor
DNA or exosomal DNA are not optimal for their use in early detection. The cost and specificity
needed to implement such assays today are likely not possible and would most likely be better
suited for the proteomic field where biosample requirements are not as strenuous.
It is not to say that liquid biopsies have no use at all. It is the opinion of the author that such
assays are better suited for tumor monitoring and therapy selection. Yet certain caveats remain
regarding the use of liquid biopsies for these purposes today. As many studies on the clinical
significance of circulating nucleic acids have been retrospective in nature, few evidence exists of
the utility of such assays in a randomized prospective clinical trial setting. While the current data
in this dissertation may suggest clinical validity in context of prediction when certain biomarker
thresholds have been met, we believe that one of the greatest barriers to clinical implementation
will rely on establishing clinical utility through prospective trials. Although it is important to note
the requirements to establish pre-analytical and analytical validity, several methodologies and
assays have been able to establish this, but still with a lack of evidence of clinical utility.
Parameters of pre-analytic and analytical validity rely on the reproducibility of results. This begins
to incorporate variability related to time of draws, needles and blood tubes used, time to
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processing, and other standard operating procedures of the blood processing and assay itself.
Within our own studies we attempt to use only acid citrate dextrose (ACD) tubes for plasma
collection and process blood within one hour of time of collection, but the latter is not always
feasible, particularly outside of the clinical trial realm. This requires clinical studies infrastructure
which include a clinical coordinator and respective personnel. Next clinical, validation must be
established through Clinical Laboratory Improvement Amendments (CLIA) certification in order
to establish a quality standard of accuracy, reliability, and timeliness of results. Again this has
been established in certain scenarios for ctDNA, but the current nature of the isolation and
processing of exosomes would likely make it difficult for such SOPs and validation to become
viable. Due to the complexity and user variability involved in exosome isolation through
ultracentrifugation, the exosome field may find more success with microfluidic based methods
which can become more standardized. Similar to the immune-capture approach presented in
Chapter 6, one can envision a microfluidic chip coated with antibodies of interest similar to
methodologies established for circulating tumor cells (206). In regards to clinical utility, in this
current study, we attempt to provide retrospective evidence for disease monitoring in the context
of pancreatic cancer, but we envision establishing clinical utility through a prospective clinical
trial with the same intended use. This could involve monitoring of metastatic pancreatic cancer
patients through serial liquid biopsies, where detection of exoDNA MAF >1% would stratify
patients into receiving early follow-up imaging for detection of progression and a change to
second-line chemotherapy.
In summary, as an emerging biomarker in the field of solid cancers, the potential of liquid biopsies
as being a minimally invasive means of prognostication and tumor monitoring can bring about
significant survival benefits. These benefits would likely be better leveraged when using
complementary biomarkers such as presented in this work including standard clinical biomarkers
(CA19-9) as well as liquid biopsy sources of nucleic acid material (cfDNA and exosomes).
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